

Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lcyc20>

Design and Synthesis of Some New Pyrazolo[1,5-a]pyrimidines, Pyrazolo[5,1-c]triazines, Pyrazolo[3,4-d]pyridazines, and Isoxazolo[3,4-d]pyridazines Containing the Pyrazole Moiety

Abdou O. Abdelhamid^a, Abdelgawad A. Fahmi^a & Karema N. M. Halim^a

^a Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

Accepted author version posted online: 22 Feb 2012. Version of record first published: 21 Feb 2013.

To cite this article: Abdou O. Abdelhamid, Abdelgawad A. Fahmi & Karema N. M. Halim (2013): Design and Synthesis of Some New Pyrazolo[1,5-a]pyrimidines, Pyrazolo[5,1-c]triazines, Pyrazolo[3,4-d]pyridazines, and Isoxazolo[3,4-d]pyridazines Containing the Pyrazole Moiety, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 43:8, 1101-1126

To link to this article: <http://dx.doi.org/10.1080/00397911.2011.616639>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings,


demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

DESIGN AND SYNTHESIS OF SOME NEW PYRAZOLO[1,5-*a*]PYRIMIDINES, PYRAZOLO [5,1-*c*]TRIAZINES, PYRAZOLO[3,4-*d*]PYRIDAZINES, AND ISOXAZOLO[3,4-*d*]PYRIDAZINES CONTAINING THE PYRAZOLE MOIETY

Abdou O. Abdelhamid, Abdelgawad A. Fahmi, and
 Karema N. M. Halim

Department of Chemistry, Faculty of Science, Cairo University, Giza, Egypt

GRAPHICAL ABSTRACT



Abstract Pyrazolo[1,5-*a*]pyrimidines, pyrazolo[5,1-*c*]triazines, [1,2,4]triazolo[4,3-*a*]pyrimidine, [1,2,4]triazolo[3,4-*c*][1,2,4]triazine, pyrazolo[3,4-*d*]pyridazines, and isoxazolo[3,4-*d*]pyridazines were prepared from 3-(3-(dimethylamino)acryloyl)-1-aryl-5-diphenyl-1H-pyrazole-5-carbonitrile with each of hydrazonoyl halides, hydroxymoyl chlorides, heterocyclic amines, and diazotized heterocyclic amines. All the newly synthesized compounds were confirmed by elemental analyses, spectral data, and alternative synthetic routes whenever possible.

Keywords Isoxazolo[3,4-*d*]pyridazines; pyrazolo[1,5-*a*]pyrimidines; pyrazolo[3,4-*d*]pyridazines; pyrazolo[5,1-*c*]triazines

INTRODUCTION

Some pyrazole derivatives possess biological and pharmacological activities^[1–9] and also find application in dyes.^[10,11] Robins et al. reported that certain 3-substituted pyrazolo[1,5-*a*]pyrimidines inhibit the metabolism schistosomiasis in snails.^[12,13] Also, pyrazolopyrimidine systems are reported as inhibitors for the synthesis of DNA and RNA in the cells of some types of cancer^[14] and viruses.^[15]

Received June 23, 2011.

Address correspondence to Abdou O. Abdelhamid, Department of Chemistry, Faculty of Science, Cairo University, Giza 12613, Egypt. E-mail: Abdelhamid45@gmail.com

In addition, a large number of thiazole derivatives have been found to exhibit pharmacological activity.^[16–21] In view of this we become interested in the synthesis of some new pyrazoles, pyrazolo[1,5-*a*]pyrimidines, pyrazolo[5,1-*c*]triazines, pyrazolo[3,4-*d*]pyridazines, and isoxazolo[3,4-*d*]pyridazines. This work is an extension of an ongoing research program devoted to the synthesis and characterization of different heterocyclic ring systems endowed with potential biological activities.^[22–28]


RESULTS AND DISCUSSION

Treatment of 3-((*E*)-3-(dimethylamino)acryloyl)-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile **1a** with 3-amino-5-phenylpyrazole **2a** in acetic acid containing ammonium acetate by boiling under reflux gave 1,5-diphenyl-3-(2-phenylpyrazolo[1,5-*a*]pyrimidin-7-yl)-1*H*-pyrazole-4-carbonitrile **4a**. The structure **4a** was established by elemental analysis, spectral data, and alternative synthesis [¹H NMR δ = 6.55 (s, 1H, pyrazole H-4), 7.26–7.80 (m, 12 H, ArH's), 8.23 (d, 2H, *J* = 6 Hz), 8.34 (d, 2H, *J* = 6 Hz), 9.29 (d, 1H)]. The formation of compound **4** is assumed to take place via an initial Michael addition of the exocyclic amino group in compound **2** to the activated double bond in **1a** to give the acyclic nonisolable intermediate **3**, which undergoes cyclization and aromatization via loss of both dimethylamine and water molecules, producing the final isolable product **4a**. Although the endocyclic imino group in compound **2a** is the most nucleophilic center, nevertheless, it is the most sterically hindered site,^[29] as shown in Scheme 1. Thus, treatment of *N,N*-dimethyl-*N'*-(3-phenyl-1*H*-pyrazol-5-yl)formamidine **6** with 3-acetyl-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile **7** in ethanol under reflux gives a product identical in all aspects (mp, mixed mp, and spectra) with **4a** (Scheme 1). Analogously, **1a** and **1b** reacted with the appropriate aminopyrazoles **2b** and **c**, 3-aminotriazole, and 2-aminobenzimidazole to afford pyrazolo[1,5-*a*]pyrimidines **4b**, **4c**, **5a–c**, [1,2,4]triazolo[4,3-*a*]pyrimidine **8a** and **8b**, and benzo[4,5]imidazo[1,2-*a*]pyrimidine **9a** and **9b**, respectively.


On the other hand, treatment of **2** with diazotized 3-amino-5-phenylpyrazole **10a** in an ethanolic sodium acetate solution gave 1,5-diphenyl-3-(8-phenyl-pyrazolo[5,1-*c*][1,2,4]triazine-3-carbonyl)-1*H*-pyrazole-4-carbonitrile **12a** (Scheme 2). Structure **12a** was elucidated by elemental analysis and spectral data. The formation of **12a** was formed via coupling diazonium chloride **10a** to **2** to form the intermediate **11**, which converted to the final product **6** through elimination of dimethylamine.

Analogously, treatment of the appropriate diazonium salt **10a–c**, triazole-3-diazonium nitrate, or benzimidazole-2-diazonium sulfate with each of **2a** and **2b** in ethanolic sodium acetate afforded pyrazolo[5,1-*c*][1,2,4]triazines **12b–g**, [1,2,4]triazolo[3,4-*c*][1,2,4]triazine **13a** and **b** and benzo[4,5]imidazo[2,1-*c*][1,2,4]triazine **14a** and **b**, respectively (Scheme 2).

Also, treatment of **2a** with benzenediazonium chloride in ethanol containing sodium acetate as a buffer solution yielded 3-[3-oxo-2-(phenyl-hydrazono)-propionyl]-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile **15a**. Structure **15a** was confirmed by elemental analysis, spectral data, and chemical transformation. ¹H NMR spectrum of **15a** showed signals at δ = 6.65–8.27 (m, 15 H, ArH's), 9.98 (s, 1H, -CHO), and 14.39



Scheme 1. Pyrazolo[1,5-*a*]pyrimidines, triazolo[4,3-*a*]pyrimidine, and benzo[4,5]imidazo[1,2-*a*]pyrimidine derivatives.



Scheme 2. Pyrazolo[5,1-*c*]triazine, triazolo[3,4-*c*]triazine, and benzo[4,5]imidazo[2,1-*c*]triazine derivatives.


(s, br., 1H, NH). Thus, **15a** was reacted with hydrazine hydrate in boiling ethanol under reflux to give 1,5-diphenyl-4'-(phenyl-hydrazono)-1*H*,4'*H*-[3,3']bipyrazolyl-4-carbonitrile **16a** (Scheme 3). Also, **2a** reacted with hydrazine hydrate to give 1,5-diphenyl-3-(1*H*-pyrazol-3-yl)-1*H*-pyrazole-4-carbonitrile **17a**. Compound **17a** was reacted with benzenediazonium chloride in ethanolic sodium acetate solution to afford a product identical in all respects (mp, mixed mp, and spectra) with **17a**.

Treatment of *C*-ethoxycarbonyl-*N*-phenylhydrazonoyl chloride (**18a**) with **2a** and triethylamine in boiling benzene under reflux afforded ethyl 4-(4-cyano-1,5-diphenyl-1*H*-pyrazole-3-carbonyl)-1-phenyl-1*H*-pyrazole-3-carboxylate (**22a**) (Scheme 4). ¹H NMR spectrum of **22a** showed signals at δ = 1.13 (t, 3H, J = 7 Hz, CH₂CH₃), 4.18 (q, 2H, J = 7 Hz, CH₂CH₃), 7.44–7.88 (m, 15H, ArHs), and 8.44 (s, 1H, pyrazole H-5). Similarly, the appropriate hydrazonoyl halides **18a–e** reacted with each of **2a** and **2b** to give pyrazole derivatives **22b–e** and **23a–e**.


Compound **22a** with hydrazine hydrate in boiling ethanol afforded one isolable product according to thin-layer chromatography (TLC), formulated as 3-(7-oxo-2-phenyl-6,7-dihydro-2*H*-pyrazolo[3,4-*d*]pyridazin-4-yl)-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile (**24a**). Structure of **24a** was elucidated by elemental analysis, spectral data, and alternative synthesis. ¹H NMR spectrum of **24a** showed signals at δ = 7.23–8.41 (m, 15 H, ArHs), 8.52 (s, 1H, pyrazole H-5), and 12.12 (s, br., 1H, NH). Thus, treatment of either **22a** (or **22b**) and **23a** (or **23g**) with boiling hydrazine hydrate in ethanol gave a product identical in all aspects (mp, mixed mp, and spectra) with **24a** and **25a**, respectively.

Also, pyrazolo[3,4-*d*]pyridazines **24b,c,e** and **25a–d** were obtained from the appropriate pyrazoles **22b,c,e** and **23a–c,e** with hydrazine hydrate (Scheme 4).

Treatment of the appropriate hydroximoyl chlorides **26a–e** with each of **2a** and **2b** in toluene at room temperature in the presence of triethylamine (or boiling without triethylamine) gave 4,5-diacylisoxazoles **27a–e** and **28a–e**, respectively. Compounds **27a–e** and **28a–e** were converted to isoxazolo[3,4-*d*]pyridazines **29a–e** and **30a–e**, respectively (Scheme 4).



Scheme 3. Pyrazoles **16** and **17**.

Scheme 4. Pyrazolo[3,4-*d*]pyridazines and isoxazolo[3,4-*d*]pyrimidines.

EXPERIMENTAL

All melting points were determined on an electrothermal apparatus and are uncorrected. Infrared (IR) spectra were recorded (KBr discs) on a Shimadzu Fourier Transform (FT)–IR 8201 PC spectrophotometer. ¹H NMR and ¹³C NMR spectra were recorded in CDCl₃ and (CD₃)₂SO solutions on a Varian Gemini 300-MHz spectrometer and chemical shifts are expressed in δ units using tetramethylsilane (TMS) as an internal reference. Elemental analyses were carried out at the Microanalytical Center of the Cairo University.

3-(3-(Dimethylamino)acryloyl)-1,5-diphenyl-1H-Pyrazole-4-carbonitrile (1a) and 3-(3-(Dimethylamino)acryloyl)-5-phenyl-1-p-Tolyl-1H-Pyrazole-4-carbonitrile (1b)

Equimolar amounts of each 3-acetyl-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile and 3-acetyl-5-phenyl-1-*p*-tolyl-1*H*-pyrazole-4-carbonitrile and dimethylformamide-dimethylacetal (50 mmol each) were refluxed in dry xylene (40 mL) for 4 h. The hot solution was evaporated to its half volume and then cooled. The resulting solid was collected and crystallized to give **1a** and **1b**.

3-((E)-3-(Dimethylamino)acryloyl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (1a). Pale brown crystals from EtOH, yield (81%), mp: 236–238 °C; IR (KBr): 3059, 2952 (CH), 2228 (CN), 1641 (CO, conjugated), 1563 (C=C); ¹H NMR (CDCl₃): δ = 2.97 (s, 3H, CH₃), 3.18 (s, 3H, CH₃), 6.15 (d, 1H, *J* = 12 Hz, CH=CH), 7.27–7.42 (m, 10H, ArH's), and 7.94 (d, 1H, *J* = 12 Hz, CH=CH); ¹³C NMR (CDCl₃): δ = 41.2 (NCH₃), 88.1, 93.5, 117.6 (CN), 129.3, 129.5, 129.7, 129.8, 130.2, 130.3, 143.5, 143.6, 152.2, 159.4, 184.2; MS: *m/z* = 344 (*M* + 1, 1.9%), 343 (*M*⁺, 10.14%), 342 (*M* – 1, 34.88%), 326 (27.88%), 325 (100%), 300 (10.64%), 272 (21.53%), 103 (6.09), 94 (10.08%). Anal. calcd. for C₂₁H₁₈N₄O (342.39): C, 73.67; H, 5.30; N, 16.36. Found: C, 73.82; H, 5.15; N, 16.57%.

3-((E)-3-(Dimethylamino)acryloyl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (1b). Pale brown crystals from EtOH, yield (82%), mp: 224–226 °C; IR (KBr): 3060, 2952 (CH), 2225 (CN), 1639 (CO, conjugated), 1562 (C=C), 1350 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.37 (s, 3H, CH₃), 2.88 (s, 3H, CH₃), 3.17 (s, 3H, CH₃), 5.80–5.84 (d, 1H, *J* = 12 Hz, CH=CH), 7.24–7.46 (m, 9H, ArH's) and 7.81–7.85 (d, 1H, *J* = 12 Hz, CH=CH); ¹³C NMR [(CD₃)₂SO]: δ = 20.6 (CH₃), 41.3 (NCH₃), 88.3, 93.7, 117.2 (CN), 125.3, 129.2, 130.7, 132.3, 136.6, 137.5, 143.6, 152.2, 159.4, 184.4; MS: *m/z* = 356 (*M*⁺, 100%), 314 (4.49%), 287 (32.91%), 257 (13.53%), 242 (7.68%), 230 (7.64), 178 (12.27%), 167 (4.29%), 163 (12.87%), 154 (21.45%), 141 (10.99%), 127 (13.00%), 114 (9.53%), 104 (10.46%), 98 (75.99%), 84 (21.27%), 76 (16.06%), 69 (49.94%), 65 (23.88%), 54 (50.74%). Anal. calcd. for C₂₂H₂₀N₄O (356.42): C, 74.14; H, 5.66; N, 15.72. Found: C, 74.25; H, 5.75; N, 15.92%.

Pyrazolo[1,5-*a*]pyrimidine 4a–c, 5a–c, 1,2,4-triazolo[4,3-*a*]pyrimidine 8a and b, and 4a-hydropyrimidino[1,2-*a*]benzimidazoles 9a and 9b

A mixture of the appropriate 3-amino-5-phenylpyrazole, 3-amino-4-phenylpyrazole, 3-amino-4-cyanopyrazole, 3-aminotriazole, or 2-aminobenzimidazole (5 mmol); 3-(3-(dimethylamino)acryloyl)-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile (**1a**) or 3-(3-(dimethylamino)acryloyl)-5-phenyl-1-*p*-tolyl-1*H*-pyrazole-4-carbonitrile (**1b**) (5 mmol); and ammonium acetate (0.37 g, 5 mmol) in acetic acid (20 mL) was refluxed for 4 h. The resulting solid that formed was collected and recrystallized from the proper solvent to give **4a–c**, **5a–c**, **8a**, **8b**, **9a**, and **9b**, respectively.

1,5-Diphenyl-3-(2-phenylpyrazolo[1,5-*a*]pyrimidin-7-yl)-1H-pyrazole-4-carbonitrile (4a). Pale yellow crystals from diluted AcOH, yield (87%), mp: 187–189 °C; IR (KBr): 3043 (CH, aromatic), 2229 (CN), 1612 (C=N), and 1585

(C=C); ^1H NMR (CDCl_3): δ = 7.09–8.52 (m, 17H, ArH's) and 9.11 (s, 1H, ArH); ^{13}C NMR (CDCl_3): δ = 96.8 (pyrazole C-4), 102.2, 111.1, 121.6 (CN), 124.1, 127.5, 128.1, 128.6, 129.4, 129.5, 130.3, 130.4, 131.2, 131.3, 131.5, 133.6, 133.7, 141.2, 151.4, 152.6, 153.1, 155.6; MS: m/z = 439 ($M+1$, 13.2%), 438 (M^+ , 19.5%), 307 (5.7%), 229 (9.2%), 219 (4.6%), 195 (5.7%), 165 (10.9), 151 (5.7%), 118 (5.2%), 104 (8%), 103 (6.9%), 102 (8.6%), 11 (9.8%), 91 (7.5%), 90 (6.9%), 89 (10.3%), 77 (100%), 63 (11.5%), and 51 (57.5%). Anal. calcd. for $\text{C}_{28}\text{H}_{18}\text{N}_6$ (438.48): C, 79.76; H, 4.18; N, 11.63. Found: C, 79.72; H, 4.22; N, 11.65%.

1,5-Diphenyl-3-(3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-1H-pyrazole-4-carbonitrile (4b). Pale brown crystals from AcOH, yield (87%), mp: 202–204 °C; IR (KBr): 3043 (CH, aromatic), 2228 (CN), 1610 (C=N) and 1587 (C=C); ^1H NMR (CDCl_3): δ = 7.09–8.41 (m, 17H, ArH's) and 9.10 (s, 1H, ArH); ^{13}C NMR (CDCl_3): δ = 108.2, 108.1, 110.6, 122.1 (CN), 124.3, 126.1, 126.4, 128.2, 129.3, 129.4, 129.6, 130.2, 130.4, 131.3, 131.5, 133.5, 141.2, 148.4, 151.2, 153.3, 154.8 (pyrazole C-3); MS: m/z = 439 ($M+1$, 13.2%), 438 (M^+ , 19.5%), 307 (5.7%), 229 (9.2%), 219 (4.6%), 195 (5.7%), 165 (10.9), 151 (5.7%), 118 (5.2%), 104 (8%), 103 (6.9%), 102 (8.6%), 11 (9.8%), 91 (7.5%), 90 (6.9%), 89 (10.3%), 77 (100%), 63 (11.5%), and 51 (57.5%). Anal. calcd. for $\text{C}_{28}\text{H}_{18}\text{N}_6$ (438.48): C, 79.76; H, 4.18; N, 11.63. Found: C, 79.72; H, 4.22; N, 11.65%.

7-(4-Cyano-1,5-diphenyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile (4c). Pale cream crystals from EtOH, yield (86%), mp: 208–210 °C; IR (KBr): 3062 (CH, aromatic), 2227 (CN), 1613 (C=N) and 1565 (C=C); ^1H NMR (CDCl_3): δ = 7.27–8.05 (m, 7H, ArH's), 8.32 (m, 4H, ArH's), 8.42 (s, 1H, pyrazole H-5), 9.04 (s, 1H, pyrimidine H-4); ^{13}C NMR (CDCl_3): δ = 81.2, 102.1, 110.7, 112.1, 120.0 (CN), 122.2 (CN), 1233.8, 127.8, 129.2, 129.3, 130.2, 130.3, 131.1, 131.3, 131.4, 141.2, 151.4, 153.4, 156.4, 158.7 (pyrazole C-3); MS: m/z = 389 ($M+2$, 5.3%), 388 ($M+1$, 16%), 387 (55%), 396 ($M-1$, 100%), 385 (54%), 325 (5.3%), 213 (7.4%), 197 (6.4%), 178 (8.5%), 167 (10.6%), 150 (11.7%), 143 (10.6%), 142 (16%), 127 (9.6%), 124 (10.6%), 97 (10.6%), 77 (75.5%), 64 (12.8%). Anal. calcd. for $\text{C}_{23}\text{H}_{13}\text{N}_7$ (387.4): C, 71.31; H, 3.38; N, 25.31. Found: C, 71.12; H, 4.11; N, 25.55%.

5-Phenyl-3-(2-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-1-*p*-tolyl-1H-pyrazole-4-carbonitrile (4d). Pale cream crystals from diluted AcOH, yield (87.7%), mp: 194–196 °C; IR (KBr): 3043 (CH, aromatic), 2226 (CN), 1622 (C=N), and 1600 (C=C); ^1H NMR (CDCl_3): δ = 2.36 (s, 3H, CH_3), 6.41 (s, 1H, pyrazole H-4), 7.21–8.02 (m, 13H, ArH's), 8.31 (d, 2H, J = 8 Hz, ArH's) and 9.11 (s, 1H, ArH); ^{13}C NMR (CDCl_3): δ = 19.8 (CH_3), 97.2 (pyrazole c-4), 102.1, 110.8, 122.2 (CN), 124.2, 127.3, 128.2, 128.5, 130.3, 131.1, 131.2, 131.3, 131.4, 133.2, 136.3, 141.2, 151.2, 152.3, 153.1, 155.4; MS: m/z = 454 ($M+2$, 5.9%), 452 (M^+ , 100%), 425 (34.1%), 218 (25.3%), 203 (15.9%), 193 (34.1%), (13%), 177 (13%), 166 (28.7%), 151 (7.5%), 142 (19.8%), 140 (23.9%), 127 (16.7%), 115 (46.7%), 103 (33%), 914 (50%), 89 (33.2%), 77 (35.1%), 65 (34%). Anal. calcd. for $\text{C}_{29}\text{H}_{20}\text{N}_6$ (452.51): C, 76.97; H, 4.45; N, 18.57. Found: C, 77.10; H, 4.32; N, 18.65%.

5-Phenyl-3-(3-phenylpyrazolo[1,5-a]pyrimidin-7-yl)-1-*p*-tolyl-1H-pyrazole-4-carbonitrile (4e). Dark yellow crystals from AcOH, yield (87%), mp: 202–204 °C;

IR (KBr): 3045 (CH, aromatic), 2225 (CN), 1625 (C=N), and 1600 (C=C); ^1H NMR (CDCl_3): δ = 2.34 (s, 3H, CH_3), 6.93 (d, 2H, J = 8 Hz, ArH), 7.23–8.22 (m, 14H, ArH's), and 9.11 (s, 1H, ArH); ^{13}C NMR (CDCl_3): δ = 20.1 (CH_3), 102.1, 108.4, 110.7, 122.1 (CN), 124.4, 126.3, 126.4, 128.2, 129.5, 130.4, 131.2, 131.3, 131.4, 133.3, 136.5, 141.3, 148.2, 151.2, 153.6, 154.4 (pyrazolo C-3). Anal. calcd. for $\text{C}_{29}\text{H}_{20}\text{N}_6$ (452.51): C, 76.97; H, 4.45; N, 18.57. Found: C, 76.80; H, 4.12; N, 18.85%.

7-(4-Cyano-5-phenyl-1-*p*-tolyl-1*H*-pyrazol-3-yl)pyrazolo[1,5-*a*]pyrimidine-3-carbonitrile (4f). Pale yellow crystals from EtOH, yield (86%), mp 238–240 °C; IR (KBr): 3136 (CH, aromatic), 2230 (CN), 1616 (C=N), 1562 (C=C) and 1323 (CH_3); ^1H NMR [$(\text{CD}_3)_2\text{SO}$]: δ = 2.36 (s, 3H, CH_3), 7.23–8.42 (m, 11H, ArH's), and 9.51 (s, 1H, ArH); ^{13}C NMR [$(\text{CD}_3)_2\text{SO}$]: δ = 20.4 (CH_3), 81.5, 102.4, 111.1, 112.4 (CN), 122.2 (CN), 124.5, 128.3, 129.5, 130.3, 1311.2, 131.4, 131.8, 136.3, 141.2, 151, 153.1, 156.3, 158.5 (pyrazole C-3); MS: m/z = 401 (M^+ , 100%), 373 (2.5%), 228 (4.5%), 202 (9.6%), 192 (13.6%), 139 (4.6%), 104 (4.4%), 101 (7.1%), 90 (37.4), 77 (15.1%), 64 (33.4). Anal. calcd. for $\text{C}_{24}\text{H}_{15}\text{N}_7$ (401.42): C, 71.81; H, 3.77; N, 24.42. Found: C, 71.85; H, 3.52; N, 24.65%.

3-([1,2,4]Triazolo[1,5-*a*]pyrimidin-7-yl)-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile (8a). Yellow crystals from diluted AcOH, yield (85%), mp: 295–297 °C; IR (KBr): 3062 (CH, aromatic), 2225 (CN), 1623 (C=N) and 1586 (C=C); ^1H NMR [$(\text{CD}_3)_2\text{SO}$]: δ = 7.27–8.02 (m, 7H, ArH's), 8.29 (s, 1H, triazole H-3), 9.72 (d, 1H, J = 4 Hz, pyrimidine H-4); ^{13}C NMR [$(\text{CD}_3)_2\text{SO}$]: δ = 102.1 (pyrazole C-4), 110.2, 117.8 (CN), 124.4, 128.5, 129.8, 129.9, 130.2, 130.7, 131.2, 134.4, 136.8, 141.1, 145.2 (triazole C-5), 149.3, 151.2, 157.8; MS: m/z = 389 ($\text{M} + 2$, 5.3%), 388 ($\text{M} + 1$, 16%), 387 (55%), 396 ($\text{M} - 1$, 100%), 385 (54%), 325 (5.3%), 213 (7.4%), 197 (6.4%), 178 (8.5%), 167 (10.6%), 150 (11.7%), 143 (10.6%), 142 (16%), 127 (9.6%), 124 (10.6%), 97 (10.6%), 77 (75.5%), 64 (12.8%). Anal. calcd. for $\text{C}_{21}\text{H}_{13}\text{N}_7$ (387.4): C, 69.41; H, 3.61; N, 26.98. Found: C, 69.42; H, 3.72; N, 26.75%.

3-([1,2,4]Triazolo[4,3-*a*]pyrimidin-5-yl)-5-phenyl-1-*p*-tolyl-1*H*-pyrazole-4-carbonitrile (8b). Colorless crystals from diluted AcOH, yield (85%), mp 264–266 °C; IR (KBr): 3085 (CH, aromatic), 2233 (CN), 1658 (C=N) and 1589 (C=C); ^1H NMR [$(\text{CD}_3)_2\text{SO}$]: δ = 2.28 (s, 3H, CH_3), 7.27–7.30 (m, 3H, ArH's), 7.67–7.73 (m, 3H, ArH's), 7.87 (d, 2H, J = 8 Hz, ArH,s), 8.312 (d, 2H, J = 8 Hz), 9.39 (s, 1H, ArH), 9.72 (s, 1H, ArH); ^{13}C NMR [$(\text{CD}_3)_2\text{SO}$]: δ = 20.1 (CH_3), 101.2, 111.1, 117.8 (CN), 124.4, 128.4, 128.4, 129.5, 130.2, 131.3, 131.9, 143.5, 136.9, 141.2, 145.4 (triazole C-5), 149.2, 151.5, 158.2; MS: m/z = 387 ($\text{M} + 1$, 12.2%), 377 (M^+ , 100%), 301 (12.7%), 287 (14.30%), 257 (4.9%), 165 (7%), 149 (11.9), 146 (11.5%), 127 (7.2%), 114 (12.5%), 92 (17.5%), 79 (10.4%), 78 (9.1%), 77 (76.5%), 68 (19.8%), 65 (100%). Anal. calcd. for $\text{C}_{22}\text{H}_{15}\text{N}_7$ (377.4): C, 70.01; H, 4.01; N, 25.98. Found: C, 69.85; H, 3.92; N, 26.10%.

3-Benzo[4,5]imidazo[1,2-*a*]pyrimidin-4-yl-1,5-diphenyl-1*H*-pyrazole-4-carbonitrile (9a). Yellow crystals from dioxane, yield (86.9%), mp >300 °C; IR (KBr): 3085 (CH, aromatic), 2230 (CN), 1658 (C=N) and 1589 (C=C); ^1H NMR [$(\text{CD}_3)_2\text{SO}$]: δ = 7.27–7.50 (m, 6H, ArH's), 7.67 (d, 2H, J = 8 Hz, ArH's), 7.87–8.12

(m, 5H, ArH's), 8.31 (d, 2H, $J=8$ Hz, ArH's), 9.39 (s, 1H, ArH); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta=101.8, 110.9, 115.2, 117.2$ (CN), 119.5, 122.2, 124.3, 124.5, 128.6, 129.2, 129.5, 130.3, 130.5, 137.1, 137.4, 141.2, 147.4, 149.3, 155.8, 158.2; MS: $m/z=413$ ($\text{M}+1$, 2.2%), 412 (M^+ , 0.9%), 319 (2.5%), 244 (11.45%), 180 (24.99%), 141 (10.40%), 114 (11.06), 103 (11.7%), 91 (10.5%), 90 (18.65%), 77 (100%), 65 (8.9%), 64 (11.28%). Anal. calcd. for $\text{C}_{26}\text{H}_{16}\text{N}_6$ (412.45): C, 75.71; H, 3.91; N, 20.38. Found: C, 75.85; H, 3.90; N, 20.10%.

3-Benzo[4,5]imidazo[1,2-*a*]pyrimidin-4-yl-5-phenyl-1-*p*-tolyl-1*H*-pyrazole-4-carbonitrile (9b). Pale yellow crystals from diluted dimethylformamide (DMF), yield (87%), mp 276–278 °C; IR (KBr): 3085 (CH, aromatic), 2230 (CN), 1658 (C=N) and 1589 (C=C); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta=2.34$ (s, 3H, CH_3), 7.21–7.32 (m, 5H, ArH's), 7.67–7.83 (m, 6H, ArH's), 8.10 (d, 1H, $J=8$ Hz, ArH,s), 8.31 (d, 2H, $J=8$ Hz), 9.35 (s, 1H, ArH); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta=20.8$ (CH_3), 101.9, 110.3, 115.2, 117.6 (CN), 119.1, 122.4, 124.6, 124.7, 128.4, 129.4, 132.5, 137.4, 141.3, 147.2, 149.4, 155.2, 157.8; MS: $m/z=427$ ($\text{M}+1$, 1.31%), 301 (26.56%), 286 (34.66%), 244 (6.91%), 194 (19.5%), 165 (8.53%), 140 (10.6), 127 (10.35%), 114 (15.09%), 104 (25.53%), 103 (32.85%), 91 (100%), 89 (49.53%), 77 (96.06%), 65 (83.80%), 63 (40.89%). Anal. calcd. for $\text{C}_{27}\text{H}_{18}\text{N}_6$ (426.47): C, 76.04; H, 4.25; N, 19.71. Found: C, 76.15; H, 3.95; N, 19.55%.

(Pyrazolo[5,1-*c*][1,2,4]triazin-3-yl)methanone 12a-e, ([1,2,4]Triazolo[3,4-*c*][1,2,4]triazin-6-yl)(1*H*-pyrazol-3-yl)methanone 13a and b, Benzo[4,5]imidazo[2,1-*c*][1,2,4]triazin-3-yl-(1*H*-pyrazol-3-yl)-methanone 14a and b, 1*H*-Pyrazol-3-yl)-4*H*-pyrazol-4-ylidene)hydrazine 16, and 3-(1*H*-Pyrazol-3-yl)-1*H*-pyrazole 17

A solution of the appropriate diazonium salt of heterocyclic amines [(3-amino-5-phenylpyrazole (**3a**), 3-amino-4-phenylpyrazole (**3b**), 3-amino-4-cyano-pyrazole (**3c**), 3-amino-1,2,4-triazole (**3d**), and 2-amino-benzimidazole (**3e**)] (5 mmol) was added to a mixture of sodium salt of 5-hydroxy-1-naphtho[2,1-*b*]furan-2-ylpropanone (**2**) (5 mmol), sodium acetate (0.65 g, 5 mmol) in ethanol (30 mL) at 0–5 °C while stirring. The resulting solid that formed after 3 h was collected, washed with water, and recrystallized to give **12a–c**, **13a–c**, **14a**, **14b**, **16**, and **17**, respectively

1,5-Diphenyl-3-(7-phenyl-pyrazolo[5,1-*c*][1,2,4]triazine-4-carbonyl)-1*H*-pyrazole-4-carbonitrile (12a). Brown crystals from EtOH, yield (93%), mp: 214–216 °C; IR (KBr): 3057 (CH, aromatic), 2227 (CN), 1642 (C=O) and 1567 (C=C); ^1H NMR (CDCl_3): $\delta=6.67$ (s, 1H, pyrazole H-4), 7.27–8.05 (m, 13H, ArH's), 8.42 (d, 2H, $J=8$ Hz, ArH's), 9.72 (d, 1H, $J=8$ Hz, ArH); ^{13}C NMR (CDCl_3): $\delta=88.1, 103.2, 117.6$ (CN), 125.6, 126.8, 129.1, 129.2, 129.4, 131.3, 131.7, 133.4, 138.8, 143.2, 145.2, 151.7, 152.4, 153.2, 153.5, 181.2 (CO); MS: $m/z=467$ (M^+ , 5.3%), 439 (6.0%), 296 (4.27%), 272 (27.45.3%), 244 (5.4%), 216 (16.4%), 180 (15.5%), 141 (70.6%), 101 (19.7%), 88 (28.6%), 76 (56%). Anal. calcd. for $\text{C}_{28}\text{H}_{17}\text{N}_7\text{O}$ (467.48): 71.94; H, 3.67; N, 20.97. Found: C, 72.12; H, 3.78; N, 20.85%.

1,5-Diphenyl-3-(8-phenyl-pyrazolo[5,1-c][1,2,4]triazine-4-carbonyl)-1H-pyrazole-4-carbonitrile (12b). Dark brown from EtOH, yield (93%), mp: 242–244 °C; IR (KBr): 3058 (CH, aromatic), 2233 (CN), 1654 (C=O) and 1596 (C=C); ¹H NMR (CDCl₃): 7.27–8.05 (m, 13H, ArH's), 8.42 (d, 3H, *J* = 8 Hz, ArH's), 9.72 (d, 1H, *J* = 8 Hz, ArH); ¹³C NMR (CDCl₃): δ = 103.0, 118.1 (CN), 128.1, 128.3, 129.2, 129.4, 129.6, 131.6, 134.3, 139.2, 143.2, 145.4, 151.2, 152.3, 153.4, 154.6, 181.2 (CO); MS: *m/z* = 467 (M⁺, 100%), 439 (5.99%), 272 (27.54%), 269 (15.27%), 244 (5.26%), 223 (10.69%), 216 (16.05%), 190 (15.65%), 177 (5.26%), 152 (10.16%), 141 (70.53%), 127 (8.87%), 104 (7.10%), 101 (19.66%), 88 (29.90%). Anal. calcd. for C₂₈H₁₇N₇O (467.48): C, 71.94; H, 3.67; N, 20.97. Found: C, 72.12; H, 3.78; N, 20.85%.

4-(4-Cyano-1,5-diphenyl-1H-pyrazole-3-carbonyl)-pyrazolo[5,1-c][1,2,4]triazine-8-carbonitrile (12c). Yellowish green crystals from diluted AcOH, yield (95%), mp: 218–220 °C; IR (KBr): 3070 (CH, aromatic), 2237 (CN), 1664 (C=O) and 1596 (C=C); ¹H NMR (CDCl₃): 7.27–8.05 (m, 7H, ArH's), 8.22 (d, 2H, *J* = 8 Hz, ArH's), 8.42 (d, 2H, *J* = 8 Hz, ArH's), 9.72 (d, 1H, *J* = 8 Hz, ArH); ¹³C NMR (CDCl₃): δ = 88.2, 98.2, 117.3 (CN), 122.1 (CN), 129.1, 129.2, 129.5, 129.7, 129.9, 131.2, 131.6, 136.2, 143.1, 145.3, 151.2, 151.4, 152.3, 180.9 (CO); MS: *m/z* = 400 (0.86%), 325 (19.85%), 315 (4.73%), 287 (7.33%), 272 (12.09%), 245 (11.33%), 180 (11.35%), 167 (14.75%), 149 (32.74%), 141 (5.92%), 114 (6.96%), 98 (33.98%), 78 (10.88%), 77 (100%), 70 (69.51%), 65 (21.48%). Anal. calcd. for C₂₃H₁₂N₈O (416.39): C, 66.34; H, 2.90; N, 26.91. Found: C, 66.12; H, 2.78; N, 26.65%.

5-Phenyl-3-(7-phenyl-pyrazolo[5,1-c][1,2,4]triazine-4-carbonyl)-1-p-tolyl-1H-pyrazole-4-carbonitrile (12d). Brown crystals from EtOH, yield (93%), mp: 198–200 °C; IR (KBr): 3055 (CH, aromatic), 2233 (CN), 1684 (C=O) and 1595 (C=C), 1350 (CH₃); ¹H NMR [(CD₃)₂SO]: 2.37 (s, 3H, CH₃), 7.17–7.81 (m, 10H, ArH's), 8.16 (d, 2H, *J* = 8 Hz, ArH's), 8.42 (d, 2H, *J* = 8 Hz, ArH's), 9.02 (s, 1H, ArH), 9.85 (s, 1H, ArH); ¹³C NMR (CDCl₃): δ = 20.1 (CH₃), 87.9, 103.2, 117.6 (CN), 125.2, 125.4, 126.2, 129.4, 129.7, 130.9, 131.6, 132.3, 133.8, 136.7, 137.5, 139.4, 145.4, 151.2, 152.4, 153.1, 153.4 (pyrazole C-4), 181.2 (CO). Anal. calcd. for C₂₉H₁₉N₇O (481.51): C, 72.34; H, 3.98; N, 20.36. Found: C, 72.12; H, 3.78; N, 20.55%.

5-Phenyl-3-(7-phenyl-pyrazolo[5,1-c][1,2,4]triazine-3-carbonyl)-1-p-tolyl-1H-pyrazole-4-carbonitrile (12e). Pale brown crystals from EtOH, yield (93%), mp 262–264 °C; IR (KBr): 3055 (CH, aromatic), 2237 (CN), 1658 (CO), 1608 (C=N) and 1595 (C=C), 1350 (CH₃); ¹H NMR [(CD₃)₂SO]: 2.36 (s, 3H, CH₃), 7.12–7.79 (m, 10H, ArH's), 8.16 (d, 2H, *J* = 8 Hz, ArH's), 8.42 (d, 2H, *J* = 8 Hz, ArH's), 9.02 (s, 1H, ArH), 9.85 (s, 1H, ArH); ¹³C NMR (CDCl₃): δ = 20.0 (CH₃), 88.2, 101.2 (pyrazole C-3), 117.6 (CN), 125.3, 128.4, 129.3, 129.6, 130.4, 131.2, 132.5, 134.5, 136.6, 137.82, 139.4, 145.5, 151.2, 152.4, 153.3, 154.6, 181.1 (CO); MS: *m/z* = 482 (M + 1, 30.7%), 481 (100%), 480 (M – 1, 87.2%), 286 (28.4%), 285 (17.6%), 223 (16.8%), 194 (11.2%), 155 (13.9%), 142 (12.2%), 140 (13.0%), 128 (12.6%), 115 (18.7%), 114 (12.5%), 102 (20.2%), 91 (30.0%), 89 (14.8%), 77

(24.6%), 65 (33.2%). Anal. calcd. for $C_{29}H_{19}N_7O$ (481.51): C, 72.34; H, 3.98; N, 20.36. Found: C, 72.25; H, 3.74; N, 20.47%.

4-(4-Cyano-5-phenyl-1-p-tolyl-1H-pyrazole-3-carbonyl)-pyrazolo[5,1-c][1,2,4]-triazine-8-carbonitrile (12f). Yellow crystals from EtOH, yield (95%), mp 204–206 °C; IR (KBr): 3070 (CH, aromatic), 2237 (CN), 1664 (C=O) and 1596 (C=C); 1H NMR ($CDCl_3$): 2.41 (s, 3H, CH_3), 7.27–7.34 (m, 3H, ArH's), 7.70–7.82 (m, 2H, ArH's), 8.22–8.45 (m, 2H, ArH's), 8.72 (s, 1H, ArH), 8.85 (d, 2H, $J=8$ Hz, ArH), 10.82 (s, 1H, ArH); ^{13}C NMR: 20.2 (CH_3), 88.1, 97.9 (pyrazole C-3), 117.6 (CN), 120.4 (CN), 125.4, 129.4, 129.6, 132.2, 137.1, 137.4, 145.2, 151.4, 151.5, 152.2, 181.2 (CO); MS: $m/z=343$ (100%), 328 (3.59%), 310 (11.35%), 272 (49.42%), 243 (12.66%), 230 (6.17%), 179 (24.96%), 171 (8.66%), 156 (32.74%), 141 (18.54%), 127 (6.43%), 114 (11.13%), 97 (61.14%), 84 (13.72%), 77 (45.49%), 64 (32.52%), 54 (37.17%), 51 (17.77). Anal. calcd. for $C_{24}H_{14}N_8O$ (430.42): C, 66.97; H, 3.28; N, 26.03. Found: C, 67.12; H, 3.18; N, 26.25%.

1,5-Diphenyl-3-([1,2,4]triazolo[3,4-c][1,2,4]triazine-5-carbonyl)-1H-pyrazole-4-carbonitrile (13a). Yellowish green crystals from diluted AcOH, yield (92%), mp: 192–194 °C; IR (KBr): 3062 (CH, aromatic), 2233 (CN), 1659 (C=O), and 1593 (C=C); 1H NMR [$(CD_3)_2SO$]: 7.27–7.7.64 (m, 6H, ArH's), 7.95 (d, 2H, $J=8$ Hz, ArH's), 8.45 (s, 1H, ArH), 8.65 (d, 2H, $J=8$ Hz, ArH), 9.82 (s, 1H, ArH); ^{13}C NMR: 87.9, 117.6 (CN), 129.2, 129.3, 129.6, 129.9, 13.2, 131.5, 139.5 (triazole C-5), 143.4, 144.5, 145.5, 150.8, 152.2, 156.3, 178.4 (CO); MS: $m/z=365$ (M-N₂, 1.91%), 287 (4.19%), 272 (13.07%), 259 (6.15%), 245 (27.15%), 149 (10.50%), 104 (28.20%), 104 (40.23%), 91 (37.09%), 77 (100%), 65 48.24%), 50 (79.19%). Anal. calcd. for $C_{21}H_{12}N_8O$ (392.11): C, 64.28; H, 3.08; N, 28.56. Found: C, 64.15; H, 3.28; N, 28.69%.

5-Phenyl-1-p-tolyl-3-([1,2,4]triazolo[3,4-c][1,2,4]triazine-5-carbonyl)-1H-pyrazole-4-carbonitrile (13b). Yellowish green crystals from diluted AcOH, yield (92.5%), mp 250–252 °C; IR (KBr): 3062 (CH, aromatic), 2237 (CN), 1660 (C=O), 1635 (C=N), and 1380 (CH_3); 1H NMR [$(CD_3)_2SO$]: 2.41 (s, 3H, CH_3), 7.27–7.34 (m, 3H, ArH's), 7.70–7.79 (m, 2H, ArH's), 8.20–8.28 (m, 2H, ArH's), 8.45 (s, 1H, ArH), 8.65 (d, 2H, $J=8$ Hz, ArH), 9.82 (s, 1H, ArH); ^{13}C NMR: 20.1 (CH_3), 87.9, 117.6 (CN), 125.4, 129.4, 129.6, 130.4, 132.3, 136.7, 137.6, 139.4 (triazole C-5), 144.4, 145.6, 156.4, 178.4 (CO); MS: $m/z=407$ (M+1, 2.03%), 406 (M⁺, 10.86%), 258 (12.49%), 243 (10.71%), 230 (4.33%), 215 (4.65%), 180 (8.12%), 147 (28.20%), 119 (39.48%), 103 (47.27%), 92 (12.73%), 91 (50.10%), 97 (4.32%), 74 (12.80%), 67 (10.61%), 64 (100%), 54 (7.65%), 54 (13.95), 53 (60.06%), 50 (62.87%). Anal. calcd. for $C_{22}H_{14}N_8O$ (406.4): C, 65.02; H, 3.47; N, 27.57.03. Found: C, 65.12; H, 3.68; N, 27.75%.

3-(Benzo[4,5]imidazo[2,1-c][1,2,4]triazine-4-carbonyl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (14a). Pale cream crystals from diluted AcOH, yield (92.8%), mp >300 °C; IR (KBr): 3062 (CH, aromatic), 2233 (CN), 1654 (C=O), and 1593 (C=C); 1H NMR [$(CD_3)_2SO$]: 7.27–7.85 (m, 8H, ArH's), 8.15–8.35 (m, 2H, ArH's), 8.42–8.65 (m, 2H, ArH's), 8.65 (d, 1H, $J=8$ Hz, ArH), 8.65 (d, 1H, $J=8$ Hz, ArH), 9.27 (s, 1H, ArH); ^{13}C NMR: 87.9, 113.2, 117.5 (CN), 118.5, 124.4, 124.5, 129.3, 129.6, 129.7, 129.9, 130.7, 131.3, 131.6, 143.3, 144.2, 144.4, 146.3, 148.2, 152.3,

155.4, 178.8 (CO); MS: m/z = 413 (M-N₂, 0.67%), 342 (3.75%), 326 (12.87%), 259 (5.15%), 167 (8.25%), 149 (32.21%), 141 (5.69%), 114 (4.76%), 98 (67.07%), 81 (42.17%), 79 (23.02%), 77 (97.19%), 69 (48.95%). Anal. calcd. for C₂₆H₁₅N₇O (441.44): C, 70.74; H, 3.42; N, 22.21. Found: C, 70.87; H, 3.25; N, 22.00%.

3-(Benzo[4,5]imidazo[2,1-c][1,2,4]triazine-4-carbonyl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (14b). Pale cream crystals from diluted AcOH, yield (93%), mp 194–196 °C; IR (KBr): 3047 (CH, aromatic), 2233 (CN), 1654 (C=O), 1624 (C=N), and 1380 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.38 (s, 3H, CH₃), 7.27–7.75 (m, 7H, ArH's), 8.10–7.14 (m, 2H, ArH's), 8.20–8.23 (m, 2H, ArH's), 8.65 (d, 1H, J = 8 Hz, ArH), 8.72 (d, 1H, J = 8 Hz, ArH), 9.18 (s, 1H, ArH); ¹³C NMR [(CD₃)₂SO]: δ = 20.1 (CH₃), 88.1, 113.2, 117.5 (CN), 118.2, 124.3, 124.5, 129.2, 129.4, 129.8, 130.7, 132.2, 136.7, 137.6, 144.6, 144.7, 145.9, 148.4, 152.2, 179.1 (CO); MS: m/z = 456 (M⁺, 011%), 356 (16.17%), 340 (60.78%), 301 (12.09%), 286 (20.97%), 273 (12.06%), 258 (28.36%), 243 (15.36%), 231 (6.74%), 215 (8.34%), 194 (21.76%), 165 (7.91%), 152 (14.87%), 140 (18.92%), 127 (31.24%), 114 (26.17%), 100 (13.79%), 98 (88.09%), 91 (73.86%), 88 (31.33%), 76 (72.94%), 69 (49.98%), 54 (100%), 50 (40.1%). Anal. calcd. for C₂₇H₁₇N₇O (455.47): C, 71.20; H, 3.76; N, 21.53. Found: C, 71.00; H, 3.57; N, 21.35%.

3-[3-Oxo-2-(phenylhydrazono)propanoyl]-1,5-diphenyl-1H-pyrazole-4-carbonitrile (15a). Yellow crystals from diluted AcOH, yield (96%), mp 210–212 °C; IR (KBr): 3047 (CH), 2870, 2785 (CH, Fermi resonance), 2229 (CN), 1640 (CO), 1562 (C=C), and 1380 (CH₃); ¹H NMR [(CD₃)₂SO]: 6.89–8.51 (m, 15H, ArH's), 9.75 (s, 1H, CHO), 14.89 (s, br., 1H, NH); MS: m/z = 420 (M + 1, 0.1%), 343 (20.36%), 326 (56.41%), 259 (6.68%), 152 (6.50%), 140 (8.22%), 103 (6.69%), 98 (67.48%), 81 (18.55%), 77 (54.37%), 70 (33.26%), 68 (18.02%), 54 (100%). Anal. calcd. for C₂₅H₁₇N₅O₂ (419.43): C, 71.59; H, 4.09; N, 16.70. Found: C, 71.65; H, 4.18; N, 16.85%.

3-[3-Oxo-2-(p-tolylhydrazono)propanoyl]-1,5-diphenyl-1H-pyrazole-4-carbonitrile (15b). Brown crystals from EtOH, yield (96%), mp 220–222 °C; IR (KBr): 3047 (CH), 2816, 2765 (CH, Fermi resonance), 2229 (CN), 1640 (CO), 1562 (C=C), and 1353 (CH₃); ¹H NMR [(CD₃)₂SO]: 2.32 (s, 3H, CH₃C₆H₄), 7.26–8.34 (m, 14H, ArH's), 9.75 (s, 1H, CHO), 14.89 (s, br., 1H, NH); MS: m/z = 433 (M⁺, 0.07%), 343 (28.50%), 329 (12.17%), 325 (75.95%), 272 (10.49%), 259 (13.02%), 141 (13.77%), 98 (48.05%), 77 (54.48%), 69 (49.42%), 54 (100%). Anal. calcd. for C₂₆H₁₉N₅O₂ (433.46): C, 72.04; H, 4.42; N, 16.16. Found: C, 72.13; H, 4.57; N, 16.34%.

3-[3-Oxo-2-(phenylhydrazono)propanoyl]-1-p-tolyl-5-phenyl-1H-pyrazole-4-carbonitrile (15c). Brown crystals from EtOH, yield (96%), mp: 212–214 °C; IR (KBr): 3047 (CH), 2804, 2754 (CH, Fermi resonance), 2225 (CN), 1640 (CO), 1566 (C=C), and 1350 (CH₃); ¹H NMR [(CD₃)₂SO]: 2.38 (s, 3H, CH₃C₆H₄), 7.26–8.34 (m, 14H, ArH's), 9.75 (s, 1H, CHO), 14.89 (s, br., 1H, NH); MS: m/z = 433 (M⁺, 0.19%), 357 (37.80%), 340 (100%), 287 (11.33%), 98 (32.91%), 91 (12.94%), 77 (5.99%), 69 (24.96%), 65 (12.46%), 55 (31.15%). Anal. calcd. for C₂₆H₁₉N₅O₂ (433.46): C, 72.04; H, 4.42; N, 16.16. Found: C, 72.08; H, 4.48; N, 16.38%.

3-[3-Oxo-2-(p-tolylhydrazono)propanoyl]-1-p-tolyl-5-phenyl-1H-pyrazole-4-carbonitrile (15d). Red crystals from EtOH, yield (96%), mp: 202–204 °C; IR (KBr): 3047 (CH), 2804, 2754 (CH, Fermi resonance), 2230 (CN), 1640 (CO), 1566 (C=C), and 1353 (CH₃); ¹H NMR [(CD₃)₂SO]: 2.38 (s, 3H, CH₃C₆H₄), 2.40 (s, 3H, CH₃C₆H₄), 7.26–8.34 (m, 13H, ArH's), 9.75 (s, 1H, CHO), 14.89 (s, br., 1H, NH); MS: *m/z* = 447 (M⁺, 0.19%), 357 (37.55%), 340 (100%), 287 (10.04%), 273 (9.52%), 98 (43.41%), 91 (14.61%), 84 (9.05%), 81 (9.44%), 76 (7.85%), 69 (32.50%), 65 (13.71%), 54 (45.10%). Anal. calcd. for C₂₇H₂₁N₅O₂ (447.49): C, 72.47; H, 4.73; N, 15.65. Found: C, 72.52; H, 4.94; N, 15.72%.

Synthesis of Pyrazoles 17a and b

A mixture of the appropriate **1a** and **1b** (5 mmol) and hydrazine hydrate (0.5 mL, 10 mmol) in ethanol (15 mL) was refluxed for 2 h. The resulting solid was collected and recrystallized from ethanol to give **17a** and **17b**.

1,5-Diphenyl-3-(4H-pyrazol-3-yl)-1H-pyrazole-4-carbonitrile

(17a). Brown crystals from EtOH, yield (81%), mp 236–238 °C; IR (KBr): 3047 (CH), 2230 (CN), 1640 (CO), 1566 (C=C), and 1353 (CH₃); ¹H NMR [(CD₃)₂SO]: 6.45 (s, 1H, pyrazole H-4), 7.26–8.33 (m, 11H, ArH's and pyrazole H-5), 11.89 (s, br., 1H, NH). Anal. calcd. for C₁₉H₁₃N₅ (311.34): C, 73.30; H, 4.21; N, 22.49. Found: C, 73.45; H, 4.33; N, 22.4962%.

5-Phenyl-3-(4H-pyrazol-3-yl)-1-p-tolyl-1H-pyrazole-4-carbonitrile

(17b). Colorless crystals from EtOH, yield (80%), mp 278–280 °C; IR (KBr): 3047 (CH), 2804, 2754 (CH, Fermi resonance), 2230 (CN), 1640 (CO), 1566 (C=C), and 1353 (CH₃); ¹H NMR [(CD₃)₂SO]: 2.38 (s, 3H, CH₃C₆H₄), 6.44 (s, 1H, pyrazole H-4), 7.21–8.25 (m, 10H, ArH's and pyrazole H-5), 11.89 (s, br., 1H, NH). Anal. calcd. for C₂₀H₁₅N₅ (325.37): C, 73.83; H, 4.65; N, 21.52. Found: C, 73.75; H, 4.54; N, 21.74%.

Synthesis of Pyrazoles 16a–d

A mixture of the appropriate **15a–d** and hydrazine hydrate (5 mmol), (0.5 g, 0.5 mL, 10 mmol) in ethanol (15 mL) was refluxed for 2 h. The resulting solid was collected and recrystallized to give **16a–d**, respectively.

Alternative method. A solution of the appropriate arendiazonium chloride (5 mmol) was added to a mixture of the appropriate **15a** and **b** (5 mmol) and sodium acetate (0.65 g, 5 mmol) in ethanol (30 mL) at 0–5 °C while stirring. The resulting solid that formed after 3 h was collected, washed with water, and recrystallized from the proper solvent to give a product identical in all aspects (mp, mixed mp, and spectra) with the corresponding **16a–d**.

4,5-Dimethyl-1-phenyl-1H,4'h-3,3'-bipyrazol-4'-one phenylhydrazone

(16a). Dark red crystals from EtOH, yield (88%), mp 256–258 °C; IR (KBr): 3282 (NH), 3070 (CH), 2218 (CN), 1589 (C=C); ¹H NMR [(CD₃)₂SO]: 7.18–8.01 (m, 15H, ArH's), 8.54 (s, 1H, pyrazole H-5), 10.89 (s, br., 1H, NH); MS: *m/z* = 414 (M – 1, 0.01%), 311 (100%), 282 (10.34%), 77 (19.76%), 51 (17.12%). Anal. calcd.

for $C_{25}H_{17}N_7$ (415.45): C, 72.28; H, 4.12; N, 23.60. Found: C, 72.35; H, 4.31; N, 23.72%.

4,5-Dimethyl-1-phenyl-1H,4'H-3,3'-bipyrazol-4'-one(4-methylphenyl) hydrazone (16b). Light pink crystals from diluted AcOH, yield (89%), mp 260–226 °C; IR (KBr): 3283 (NH), 3066 (CH), 2218 (CN), 1589 (C=C); 1H NMR $[(CD_3)_2SO]$: 2.38 (s, 3H, $CH_3C_6H_4$), 7.26–8.34 (m, 14H, ArH's), 8.75 (s, 1H, pyrazole H-5), 10.89 (s, br., 1H, NH); MS: m/z = 429 ($M - 1$, 0.05%), 311 (100%), 282 (18.18%), 255 (13.00%), 228 (6.09%), 216 (7.27%), 190 (8.72%), 178 (10.91%), 151 (12.8%), 126 (13.39%), 134 (7.77%), 100 (9.63%), 94 (6.63%), 88 (6.45%), 76 (70.93%), 66 (11.31%), 63 (15.84%), 51 (70.65%). Anal. calcd. for $C_{26}H_{19}N_7$ (429.48): C, 72.71; H, 4.46; N, 22.83. Found: C, 72.92; H, 4.64; N, 22.77%.

4,5-Dimethyl-1-(4-methylphenyl)-1H,4'H-3,3'-bipyrazol-4'-one phenylhydrazone (16c). Yellow crystals from EtOH, yield (88%), mp 262–264 °C; IR (KBr): 3294 (NH), 3043 (CH), 2221 (CN), 1577 (C=C), 1H NMR $[(CD_3)_2SO]$: 2.38 (s, 3H, $CH_3C_6H_4$), 7.15–8.22 (m, 14H, ArH's), 8.55 (s, 1H, pyrazole H-5), 10.89 (s, br., 1H, NH); MS: m/z = 430 ($M + 1$, 0.06%), 326 (67.28%), 281 (6.79%), 255 (7.14%), 228 (10.30%), 215 (10.38%), 204 (9.15%), 189 (8.85%), 177 (13.25%), 167 (12.46%), 151 (28.88%), 126 (24.97%), 103 (17.33%), 100 (21.29%), 93 (17.60%), 91 (43.56%), 88 (38.91%), 78 (70.65%), 66 (23.52%), 65 (100%), 53 (9.307%), 52 (20.30%), 50 (62.87%). Anal. calcd. for $C_{26}H_{19}N_7$ (429.48): C, 72.71; H, 4.46; N, 22.83. Found: C, 72.94; H, 4.58; N, 22.98%.

4,5-Dimethyl-1-phenyl-1H,4'H-3,3'-bipyrazol-4'-one (4-methylphenyl)hydrazone (16d). Brown crystals from EtOH, yield (89%), mp 264–266 °C; IR (KBr): 3290 (NH), 3143 (CH), 2221 (CN), 1577 (C=C), 1H NMR $[(CD_3)_2SO]$: 2.38 (s, 3H, $CH_3C_6H_4$), 2.40 (s, 3H, 4- $CH_3C_6H_4$), 7.27–8.15 (m, 13H, ArH's), 8.47 (s, 1H, pyrazole H-5), 10.75 (s, br., 1H, NH). Anal. calcd. for $C_{27}H_{21}N_7$ (443.5): C, 73.12; H, 4.77; N, 22.11. Found: C, 73.27; H, 4.85; N, 22.46%.

5-Phenyl-3-(1-phenyl-1H-pyrazole-4-carbonyl)-1-*p*-tolyl-1H-pyrazole-4-carbonitrile **22** and **23**

Equimolar amounts of each of 3-(3-(dimethylamino)acryloyl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (**1a**) or 3-(3-(dimethylamino)acryloyl)-5-phenyl-1-*p*-tolyl-1H-pyrazole-4-carbonitrile (**1b**) and the appropriate hydrazoneyl halides **18a–e** (5 mmol) were refluxed in dry toluene (20 mL) containing triethylamine (0.75 mL) for 3 h. The hot solution was filtered off, and the filtrate was evaporated and triturated with petroleum ether (40–60 °C). The resulting solid was collected and recrystallized from ethanol to give **22a–e** and **23a–e**.

Ethyl 4-(4-cyano-1,5-diphenyl-1H-pyrazole-3-carbonyl)-1-phenyl-1H-pyrazole-3-carboxylate (22a). Pale yellow crystals from EtOH, yield (85%), mp 190–192 °C; IR (KBr): 3060, 2981 (CH), 2232 (CN), 1731 (C=O), 1649 (C=N), 1591 (C=C), 1437 (CH_2) and 138 (CH_3); 1H NMR $[(CD_3)_2SO]$: δ = 1.10 (t, 3H, J = 7.5 Hz, CH_2CH_3), 4.15 (q, 2H, J = 7.5 Hz, CH_2CH_3), 7.37–7.75 (m, 13H, ArH's), 7.82–7.96 (m, 2H, ArH's), 9.31 (s, 1H, pyrazole C-5); ^{13}C NMR $[(CD_3)_2SO]$: δ = 14.5 (CH_3), 60.6 (CH_2), 94.8, 117.6 (CN), 120.1, 123.1, 127.3, 129.2, 129.3, 129.4, 129.8,

130.8, 131.2, 132.8, 140.7, 142.6, 144.6, 147.8, 152.4, 160.4 (CO), 178.7 (CO); MS: m/z = 489 ($M+2$, 1.8%), 488 ($M+1$, 16.7.5%), 487 (M^+ , 24.1%), 442 (29.8%), 272 (12.4%), 215 (19.9%), 180 (15.8%), 141 (16.3%), 104 (48.2%), 77 (100%), 65 (4.1%). Anal. calcd. for $C_{29}H_{21}N_5O_3$ (487.51): C, 71.45; H, 4.34; N, 14.37. Found: C, 71.20; H, 4.57; N, 14.35%.

3-(3-Acetyl-1-phenyl-1H-pyrazole-4-carbonyl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (22b). Pale cream crystals from diluted AcOH, yield (84%), mp 198–200 °C; IR (KBr): 3062, 2914 (CH), 2229 (CN), 1700, 1656 (2 C=O), 1594 (C=C), and 1350 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.61 (s, 3H, CH₃), 7.35–7.63 (m, 13H, ArH's), 7.95–7.99 (d, 2H, J = 8 Hz), ArH's), 9.25 (s, 1H, pyrazole C-5); ¹³C NMR [(CD₃)₂SO]: δ = 27.1 (CH₃), 94.5, 117.6 (CN), 119.8, 127.1, 127.3, 128.7, 129.4, 129.5, 129.9, 131.2, 132.6, 142.3, 144.5, 146.3, 149.6, 150.4, 152.6, 180.1 (CO), 194.8 (CO); MS: m/z = 459 ($M+2$, 5.2%), 458 ($M+1$, 11.0%), 457 (M^+ , 23.5%), 456 ($M-1$, 13.5%), 442 (36.5%), 325 (12.9%), 272 (13.9%), 213 (14.8%), 171 (40.0%), 141 (14.2%), 104 (20.0%), 77 (100%), 51 (29.0%). Anal. calcd. for $C_{28}H_{19}N_5O_2$ (457.48): C, 73.51; H, 4.19; N, 15.31. Found: C, 73.35; H, 4.31; N, 15.48%.

3-(3-Benzoyl-1-phenyl-1H-pyrazole-4-carbonyl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (22c). Brown crystals from AcOH, yield (80%), mp 219–221 °C; IR (KBr): 3061 (CH), 2230 (CN), 1654 (C=O), 1592 (C=C); ¹H NMR [(CD₃)₂SO]: δ = 7.16–7.60 (m, 18H, ArH's), 7.96–7.98 (d, 2H, J = 8 Hz), ArH's), 9.44 (s, 1H, pyrazole C-5); ¹³C NMR [(CD₃)₂SO]: δ = 94.5, 117.6 (CN), 119.8, 125.2, 127.6, 127.9, 129.2, 129.3, 129.6, 130.2, 130.6, 131.2, 132.4, 138.2, 141.5, 144.7, 145.4, 150.2, 152.1, 153.4, 178.6 (CO), 187.3 (CO); MS: m/z = 521 ($M+2$, 2.3%), 520 ($M+1$, 13.2%), 519 (M^+ , 29%), 490 (4.7%), 442 (12.4%), 275 (112.9%), 275 (11.9%), 180 (7.9%), 106 (6.2%), 105 (82.7%), 104 (10.0%), 77 (100%), 51 (23.2%). Anal. calcd. for $C_{28}C_{33}H_{21}N_5O_2$ (519.55): C, 76.29; H, 4.07; N, 13.48. Found: C, 76.08; H, 4.12; N, 13.61%.

4-(4-Cyano-1,5-diphenyl-1H-pyrazole-3-carbonyl)-3-carbamoyl-1-phenyl-1H-pyrazole (22d). Brown crystals from AcOH, yield (86%), mp: 198–200 °C; IR (KBr): 3260 (NH), 3025 (CH), 2230 (CN), 1679 (C=O), 1639 (C=N), 16.1 (C=C); ¹H NMR [(CD₃)₂SO]: δ = 7.12–7.72 (m, 18H, ArH's), 9.35 (s, 1H, pyrazole C-5), 10.72 (s, br., 1H, NH); ¹³C NMR [(CD₃)₂SO]: δ = 94.5, 117.6 (CN), 119.8, 120.7, 124.4, 127.5, 129.3, 129.4, 129.6, 129.9, 130.2, 131.4, 132.7, 140.4, 140.8, 143.2, 134.5, 145.6, 148.3, 152.4, 157.7 (CO), 178.2 (CO). Anal. calcd. for $C_{28}C_{33}H_{22}N_6O_2$ (534.57): C, 74.14; H, 4.15; N, 15.72. Found: C, 74.00; H, 3.95; N, 15.57%.

3-({4-[(4-Cyano-1,5-diphenylpyrazol-3-yl)carbonyl]1-phenylpyrazole-3-yl}-carbonyl)-1-(4-methylphenyl)-5-phenylpyrazole-4-carbonitrile (22e). Pale cream crystals from diluted AcOH, yield (84.7%), mp 250–252 °C; IR (KBr): 3061, 2919 (CH), 2234 (CN), 1681 (C=O), 1646 (C=N), 1596 (C=C), 1379 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.27 (s, 3H, CH₃), 7.09–8.03 (m, 24H, ArH's), 9.74 (s, 1H, pyrazole C-5); ¹³C NMR [(CD₃)₂SO]: δ = 20.1 (CH₃), 91.6, 94.5, 117.6 (CN), 119.8, 124.2, 125.3, 127.6, 128.4, 129.2, 129.4, 129.8, 130.2, 131.4, 132.2, 132.7, 136.6, 137.5, 142.5, 144.6, 144.8, 148.2, 150.3, 152.1, 154.3, 174.5 (CO),

178.6 (CO); MS: m/z = 700 (M^+ , 0.59%), 676 (0.69%), 580 (0.71%), 325 (4.38%), 286 (6.61%), 180 (3.77%), 167 (14.13%), 149 (40.14%), 111 (10.79%), 92 (11.64%), 84 (18.16%), 77 (37.98%), 77 (100%), 57 (52.79%), 50 (18.33%). Anal. calcd. for $C_{44}H_{28}N_8O_2$ (700.75): C, 75.42; H, 4.03; N, 15.99. Found: C, 75.21; H, 3.83; N, 16.19%.

Ethyl 4-(4-cyano-5-phenyl-1-p-tolyl-1H-pyrazole-3-carbonyl)-1-phenyl-1H-pyrazole-3-carboxylate (23a). Yellow crystals from diluted AcOH, yield (85%), mp 210–212 °C; IR (KBr): 3039, 2920 (CH), 2233 (CN), 1708 (C=O), 1658 (CO, conjugated), 1596 (C=C), 1413 (CH₂), 1379 (CH₃); ¹H NMR [(CD₃)₂SO]: 1.16 (t, 3H, J = 7.5 Hz, CH₂CH₃), 2.34 (s, 3H, CH₃), 4.14 (q, 2H, J = 7.5 Hz, CH₂CH₃), 7.28–8.41 (m, 12H, ArH's), 8.52 (d, 1H, J = 8 Hz, ArH's), 8.48 (s, 1H, pyrazole H-5); ¹³C NMR [(CD₃)₂SO]: δ = 14.4 (CH₃), 20.1 (CH₃), 60.4 (CH₂), 94.5, 117.6 (CN), 119.8, 123.1, 125.4, 127.3, 129.4, 129.5, 130.3, 132.1, 132.7, 136.6, 138.7, 140.6, 142.8, 147.7, 152.5, 160.4 (CO), 180.1 (CO); MS: m/z = 504 (M + 2, 1.18%), 503 (M + 1, 4.34%), 202 (M^+ , 14.56%), 429 (4.31%), 301 (5.47%), 257 (5.35%), 244 (7.15%), 243 (10.65%), 215 (15.45%), 149 (17.19%), 142 (11.05%), 103 (62.03%), 91 (42.21%), 77 (100%), 65 (24.65%), 57 (21.75%). Anal. calcd. for $C_{30}H_{23}N_5O_3$ (501.54): C, 71.84; H, 4.62; N, 13.96. Found: C, 72.00; H, 4.81; N, 14.15%.

3-(3-Acetyl-1-phenyl-1H-pyrazole-4-carbonyl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (23b). Pale gray crystals from diluted AcOH, yield (85%), mp 188–190 °C; IR (KBr): 3052, 2920 (CH), 2233 (CN), 1708 (C=O), 1658 (C=N), 1596 (C=C), 1379 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.36 (s, 3H, CH₃), 2.62 (s, 3H, CH₃), 7.28–8.41 (m, 12H, ArH's), 8.52 (d, 1H, J = 8 Hz, ArH's), 8.49 (s, 1H, pyrazole H-5); ¹³C NMR [(CD₃)₂SO]: δ = 20.1 (CH₃), 27.5 (CH₃), 94.5, 117.6 (CN), 119.8, 125.5, 127.3, 128.8, 129.2, 129.4, 130.7, 132.2, 123.4, 136.6, 138.5, 142.5, 146.7, 149.4, 150.7, 152.2, 180.3 (CO), 194.8 (CO); MS: m/z = 472 (M^+ , 100%), 457 (96.57%), 443 (35.03%), 428 (11.85%), 418 (8.36%), 401 (25.55%), 367 (6.39%), 356 (13.88%), 339 (43.25%), 301 (17.23%), 286 (19.61%), 273 (9.68%), 258 (22.56%), 243 (16.99%), 230 (13.47%), 213 (32.80%), 171 (61.22%), 155 (15.76%), 141 (13.50%), 114 (16.06%), 103 (40.68%), 90 (52.98%), 76 (53.70%), 64 (30.69%). Anal. calcd. for $C_{29}H_{21}N_5O_2$ (471.51): C, 73.87; H, 4.49; N, 14.85. Found: C, 73.68; H, 4.54; N, 15.11%.

3-(3-Benzoyl-1-phenyl-1H-pyrazole-4-carbonyl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (23c). Pale cream crystals from diluted AcOH, yield (80%), mp 185–187 °C; IR (KBr): 3058 (CH), 2233 (CN), 1658 (C=O), 1600 (C=C), 1384 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.36 (s, 3H, CH₃), 7.28–8.41 (m, 19H, ArH's), 8.49 (s, 1H, pyrazole H-5); ¹³C NMR [(CD₃)₂SO]: δ = 20.0 (CH₃), 94.5, 117.6 (CN), 119.8, 125.3, 127.7, 129.3, 129.6, 130.2, 132.3, 132.7, 136.4, 138.2, 138.6, 141.6, 145.7, 150.4, 152.7, 153.6, 178.2 (CO), 187.4 (CO); MS: m/z = 534 (M + 1, 28.29%), 472 (44.46%), 457 (65.55%), 443 (18.66%), 415 (11.00%), 400 (4.95%), 214 (43.43%), 178 (10.27%), 154 (33.79%), 141 (17.37%), 115 (18.76%), 104 (87.95%), 90 (64.43%), 77 (100%), 65 (26.02%). Anal. calcd. for $C_{34}H_{23}N_5O_2$ (533.58): C, 76.53; H, 4.34; N, 13.13. Found: C, 76.35; H, 4.45; N, 13.27%.

4-(4-Cyano-5-phenyl-1-p-tolyl-1H-pyrazole-3-carbonyl)-3-carbamoyl-1-phenyl-1H-pyrazole (23d). Brown crystals from diluted AcOH, yield (87%), mp 132–134 °C; IR (KBr): 3475 (NH), 3042 (CH), 2231 (CN), 1676 (C=O), 1624 (C=N), 1601 (C=C), 1368 (CH₃); ¹H NMR (CD₃Cl): δ = 2.39 (s, 3H, CH₃), 7.14–7.92 (m, 19H, ArH's), 9.27 (s, 1H, pyrazole H-5), 11.58 (s, br., 1H, NH); ¹³C NMR [(CD₃)₂SO]: (=20.1 (CH₃), 94.5, 117.6 (CN), 119.8, 120.8, 124.5, 125.7, 127.6, 129.4, 129.7, 130.4, 130.5, 132.4, 132.8, 136.7, 138.5, 140.3, 140.6, 143.5, 145.6, 148.2, 152.1, 157.7 (CO), 177.9 (CO); MS: *m/z* = 549 (M + 1, 5%), 548 (M⁺, 18.5%), 274 (17.4%), 193 (13.5%), 104 (12.4%), 89 (7.9%), 77 (26%), 76 (14%), 65 (22.5%). Anal. calcd. for C₃₄H₂₄N₆O₂ (548.59): C, 74.44; H, 4.41; N, 15.32. Found: C, 74.65; H, 4.31; N, 15.48%.

3-[(4-{[4-Cyano-1-(4-methylphenyl)-5-phenylpyrazol-3-yl]carbonyl}-1-phenyl-pyrazol-3-yl)carbonyl]-1-(4-methylphenyl)-5-phenylpyrazole-4-carbonitrile (23e). Pale brown crystals from AcOH, yield (85%), mp 256–258 °C; IR (KBr): 3055 (CH), 2233 (CN), 1678 (C=O), 1639 (C=N), 1600 (C=C), 1380 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.39 (s, 3H, CH₃), 2.40 (s, 3H, CH₃), 7.14–7.92 (m, 23H, ArH's), 9.27 (s, 1H, pyrazole H-5); ¹³C NMR [(CD₃)₂SO]: (=20.1 (CH₃), 91.7, 94.5, 117.6 (CN), 120.1, 124.2, 125.4, 127.4, 128.2, 129.4, 130.7, 132.3, 132.8, 136.6, 138.7, 142.4, 144.6, 148.3, 150.2, 152.2, 154.8, 174.5 (CO), 178.1 (CO); MS: *m/z* = 715 (M + 1, 0.81%), 714 (M⁺, 0.80%), 456 (4.60%), 286 (11.07%), 258 (11.22%), 243 (15.13%), 231 (8.52%), 195 (7.09%), 171 (4.52%), 155 (14.24%), 104 (36.75%), 91 (58.81%), 77 (100%), 65 (36.95%). Anal. calcd. for C₄₅H₃₀N₈O₂ (714.77): C, 75.62; H, 4.23; N, 15.68. Found: C, 75.80; H, 4.35; N, 15.87%.

3-(Isoxazole-4-carbonyl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile 27 and 28

Method A. Triethylamine (0.5 g, (0.75 ml, 5 mmol) was added dropwise to an equimolar amount of **1a** (or **1b**) and the appropriate hydroximoyl chloride **26a–d** (5 mmol, each) in dry toluene (20 ml) while stirring. The reaction mixture was stirred for 6 h, the solvent was evaporated and then it was triturated with petroleum ether (40–60 °C). The resulting solid was collected and crystallized to give **27a–e** and **28a–d** respectively.

Method B. Equimolar amount of **1a** (or **1b**) and the appropriate hydroximoyl chloride **26a–d** (5 mmol, each) in dry toluene (20 ml) were heated under reflux for 18 h. The reaction mixture was filtered off, the solvent was evaporated, and the filtrate was triturated with petroleum ether (40–60 °C). The resulting solid was collected and crystallized to give products identical in all aspects (mp, mixed mp, and spectra) with **27a–e** and **28a–d**, respectively.

3-(3-Benzoyl-isoxazole-4-carbonyl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (27a). Brown crystals from diluted AcOH, yield (84%), mp 178–180 °C; IR (KBr): 3062, 2918 (CH), 2233 (CN), 1681 (C=O), 1658 (C=N), 1593 (C=C); ¹H NMR [(CD₃)₂SO]: δ = 7.14–7.71 (m, 9H, ArH's), 8.26 (d, 2H, *J* = 8 Hz), 8.52 (d, 4H, *J* = 8 Hz), 8.95 (s, 1H, isoxazole H-5); ¹³C NMR [(CD₃)₂SO]: (=94.5, 117.6 (CN), 118.8, 128.5, 129.4, 129.6, 130.2, 130.5, 132.9, 137.2, 142.4, 144.6, 152.2,

162.2, 179.6 (CO), 187.4 (CO), 191.8 isoxazole C-5); MS: m/z = 445 ($M + 1$, 0.44%), 444 (M^+ , 1.63%), 339 (0.75%), 311 (2.94%), 287 (0.96%), 272 (4.41%), 180 (2.03%), 105 (100%), 77 (51.36%), 51 (19.27%). Anal. calcd. for $C_{27}H_{16}N_4O_3$ (444.44): C, 72.97; H, 3.63; N, 12.61. Found: C, 73.12; H, 3.75; N, 12.45%.

3-[3-(Furan-2-carbonyl)-isoxazole-4-carbonyl]-1,5-diphenyl-1H-pyrazole-4-carbonitrile (27b). Gray crystals from AcOH, yield (84%), mp 178–180 °C; IR (KBr): 3015, 2923 (CH), 2237 (CN), 1658 (C=O), 1558 (C=C); 1H NMR $[(CD_3)_2SO]$: δ = 6.63 (d, 1H, J = 6 Hz, furan H-4), 7.14–7.28 (m, 7H, ArH's), 8.01 (d, 1H, J = 6 Hz, furan H-5), 8.26 (d, 2H, J = 8 Hz), 8.52 (d, 2H, J = 8 Hz), 8.95 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: (=94.5, 109.8, 114.5, 117.6 (CN), 129.3, 129.5, 129.7, 129.9, 130.7, 131.3, 132.7, 137.5, 144.8, 145.7, 151.2, 151.4, 152.4, 160.2 (CO), 180.0 (CO), 183.8 (isoxazole C-5); MS: m/z = 435 ($M + 2$, 0.44%), 434 ($M + 1$, 2.02%), 405 (M^+ , 5.13%), 272 (1.49%), 244 (0.52%), 180 (0.59%), 95 (100%), 77 (13.74%), 51 (7.29%). Anal. calcd. for $C_{25}H_{14}N_4O_4$ (434.4): C, 69.12; H, 3.25; N, 12.90. Found: C, 69.00; H, 3.41; N, 13.15%.

1,5-Diphenyl-3-[3-(thienyl-2-carbonyl)-isoxazole-4-carbonyl]-1H-pyrazole-4-carbonitrile (27c). Beige crystals from diluted AcOH, yield (84%), mp: 156–158 °C; IR (KBr): 3097, 2923 (CH), 2233 (CN), 1658 (C=O), 1596 (C=C); 1H NMR $[(CD_3)_2SO]$: δ = 7.14–7.98 (m, 11H, ArH's), 8.24 (d, 2H, J = 8 Hz), 8.94 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: (=94.5, 114.5, 117.6 (CN), 125.3, 129.3, 129.5, 130.8, 131.3, 132.2, 132.7, 142.1, 144.7, 147.8, 151.5, 152.4, 166.9, 179.7 (CO), 179.9 (CO), 183.7 (isoxazole C-5); MS: m/z = 452 ($M + 2$, 0.47%), 451 ($M + 1$, 1.58%), 450 (M^+ , 5.30%), 339 (0.57%), 272 (1.41%), 141 (1.65%), 111 (100%), 77 (16.47%), 51 (7.85%). Anal. calcd. for $C_{25}H_{14}N_4O_3S$ (450.47): C, 66.66; H, 3.13; N, 12.44; S, 7.12. Found: C, 66.84; H, 3.00; N, 12.60; S, 7.32%.

3-[3-(Naphthalene-2-carbonyl)-isoxazole-4-carbonyl]-1,5-diphenyl-1H-pyrazole-4-carbonitrile (27d). Brown crystals from AcOH, yield (85%), mp 208–210 °C; IR (KBr): 3068, 2916 (CH), 2233 (CN), 1639 (C=O), 1562 (C=C); 1H NMR $[(CD_3)_2SO]$: δ = 7.14–8.12 (m, 13H, ArH's), 8.42 (d, 2H, J = 8 Hz), 8.57 (d, 1H, J = 8 Hz), 8.94 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: (=94.5, 117.6 (CN), 119.1, 126.4, 127.8, 128.3, 128.7, 129.3, 129.5, 129.7, 129.8, 129.9, 130.7, 131.2, 131.3, 132.6, 133.2, 133.1, 133.3, 142.2, 144.7, 152.2, 161.9, 179.5 (CO), 187.3 (CO), 191.8 (isoxazole C-5); MS: m/z = 496 ($M + 2$, 0.02%), 495 ($M + 1$, 0.07%), 494 (M^+ , 0.17%), 325 (100%), 272 (9.74%), 180 (5.20%), 98 (16.10%), 77 (6.58%), 55 (10.74%). Anal. calcd. for $C_{31}H_{18}N_4O_3$ (494.5): C, 75.29; H, 3.67; N, 11.33. Found: C, 75.31; H, 3.75; N, 11.46%.

5-[(3-{[4-Cyano-1-(4-methylphenyl)-5-phenylpyrazol-3-yl]carbonyl}isoxazol-4-yl)carbonyl]-2,3-diphenyl-5-hydropyrazole-4-carbonitrile (27e). Pale cream crystals from diluted AcOH, yield (88%), mp 168–170 °C; IR (KBr): 3060, 2922 (CH), 2235 (CN), 1697 (C=O), 1557 (C=N), 1540 (C=C), 1385 (CH₃); 1H NMR $[(CD_3)_2SO]$: δ = 2.41 (s, 3H, CH₃), 7.14–7.79 (m, 11H, ArH's), 8.142 (d, 2H, J = 8 Hz), 8.40 (d, 2H, J = 8 Hz), 8.51 (d, 4H, J = 8 Hz), 8.94 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: (=20.1 (CH₃), 91.6, 94.5, 117.6 (CN), 117.9 (CN), 125.6, 129.3, 129.5, 129.9, 130.9, 132.4, 132.6, 137.5, 144.7, 147.2, 151.5, 152.2, 159.7, 174.6 (CO), 179.8 (CO), 193.2 (isoxazole C-5); MS: m/z = 624 ($M - 1$,

0.02%), 337 (73.087%), 329 (30.12%), 303 (49.82%), 286 (7.77%), 273 (100%), 260 (31.43%), 246 (10.67%), 189 (14.63%), 154 (34.85%), 141 (43.12%), 104 (37.66%), 90 (44.28%), 76 (64.80%), 50 (33.48%). Anal. calcd. for $C_{38}H_{23}N_7O_3$ (625.63): C, 72.95; H, 3.71; N, 15.67. Found: C, 73.15; H, 3.50; N, 15.79%.

3-(3-Benzoyl-isoxazole-4-carbonyl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (28a). Yellow crystals from diluted AcOH, yield (84%), mp 210–212 °C; IR (KBr): 3056, 2918 (CH), 2233 (CN), 1659 (C=O), 1565 (C=C), 1385; 1H NMR [$(CD_3)_2SO$]: δ = 2.33 (s, 3H, CH_3), 7.21–7.93 (m, 14H, ArH's), 9.48 (s, 1H, isoxazole H-5); ^{13}C NMR [$(CD_3)_2SO$]: (=20.1 (CH_3), 94.5, 117.6 (CN), 118.5, 125.6, 128.5, 129.3, 129.7, 131.1, 132.2, 132.8, 136.7, 138.8, 142.4, 152.5, 161.7, 179.5 (CO), 187.3 (CO), 192.0 (isoxazole C-5); MS: m/z = 459 ($M+1$, 1.39%), 458 (M^+ , 4.15%), 339 (12.74%), 300 (17.78%), 286 (15.63%), 273 (4.45%), 194 (4.75%), 105 (100%), 91 (14.56%), 77 (45.32%), 51 (17.77%). Anal. calcd. for $C_{28}H_{18}N_4O_3$ (458.47): C, 73.35; H, 3.96; N, 12.22. Found: C, 73.53; H, 4.15; N, 12.35%.

3-[[3-(2-Furoyl)isoxazol-4-yl]carbonyl]-1-(4-methylphenyl)-5-phenyl-1H-pyrazole-4-carbonitrile (28b). Yellow crystals from diluted DMF, yield (84%), mp 188–190 °C; IR (KBr): 2925 (CH), 2230 (CN), 1670 (C=O), 1562 (C=C), 1385; 1H NMR [$(CD_3)_2SO$]: δ = 2.33 (s, 3H, CH_3), 6.32 (s, 1H, furan H-3), 7.21–7.93 (m, 12H, ArH's), 9.23 (s, 1H, isoxazole H-5); ^{13}C NMR [$(CD_3)_2SO$]: (=20.1 (CH_3), 94.5, 109.8, 114.5, 117.6 (CN), 125.4, 129.3, 129.5, 130.7, 132.1, 132.7, 136.5, 137.4, 138.8, 146.1, 151.2, 152.1, 160.2, 179 (CO), 180 (CO), 183.3 (isoxazole C-5); MS: m/z = 448 (M^+ , 4.2%), 447 (4.2%), 325 (7.9%), 301 (7.4%), 286 (11.6%), 121 (10.6%), 112 (21.7%), 95 (100%), 84 (25.9%), 93 (12.7%), 91 (12.2%), 77 (6.9%), 65 (18.0%). Anal. calcd. for $C_{26}H_{16}N_4O_4$ (448.43): C, 69.64; H, 3.60; N, 12.49. Found: C, 69.45; H, 3.72; N, 12.57%.

5-Phenyl-3-[3-(thienyl-2-carbonyl)-isoxazole-4-carbonyl]-1-p-tolyl-1H-pyrazole-4-carbonitrile (28c). Pale cream crystals from diluted AcOH, yield (85%), mp 174–176 °C; IR (KBr): 3058, 2920 (CH), 2237 (CN), 1705 (C=O), 1658 (C=N), 1516 (C=C), 1384 (CH_3); 1H NMR [$(CD_3)_2SO$]: δ = 2.34 (s, 3H, CH_3), 7.14–7.18 (m, 10H, ArH's), 8.26 (d, 2H, J = 8 Hz), 8.52 (d, 2H, J = 8 Hz), 8.95 (s, 1H, isoxazole H-5); ^{13}C NMR [$(CD_3)_2SO$]: (=20.1 (CH_3), 94.5, 109.8, 114.5, 117.6 (CN), 125.0, 125.5, 129.4, 129.7, 130.1, 132.0, 132.4, 132.8, 136.4, 138.7, 142.2, 147.8, 151.6, 152.2, 166.9, 179.8 (CO), 180.0 (CO), 183.2 (isoxazole C-5); MS: m/z = 456 ($M+2$, 0.66%), 465 ($M+1$, 1.52%), 464 (M^+ , 5.36%), 354 (0.71%), 325 (2.71%), 301 (4.37%), 286 (10.02%), 272 (0.69%), 258 (1.41%), 243 (1.48%), 180 (2.48%), 111 (100%), 91 (9.46%), 77 (8.36%), 51 (5.11%). Anal. calcd. for $C_{26}H_{16}N_4O_3S$ (464.09): C, 67.23; H, 3.47; N, 12.06; S, 6.90. Found: C, 67.10; H, 3.62; N, 11.89; S, 7.15%.

3-[3-(Naphthalene-2-carbonyl)-isoxazole-4-carbonyl]-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (28d). Pale cream crystals from diluted AcOH, yield (86%), mp 204–206 °C; IR (KBr): 3055, 2920 (CH), 2233 (CN), 1666 (C=O), 1627 (C=N), 1566 (C=C), 1353 (CH_3); 1H NMR [$(CD_3)_2SO$]: δ = 2.34 (s, 3H, CH_3), 7.14–7.29 (m, 14H, ArH's), 8.52 (d, 2H, J = 8 Hz), 8.95 (s, 1H, isoxazole H-5); ^{13}C NMR [$(CD_3)_2SO$]: (=20.1 (CH_3), 94.5, 109.8, 114.5, 117.6 (CN), 125.5, 126.4, 127.8, 129.4, 129.7, 130.2, 131.4, 131.6, 132.4, 133.2, 134.2, 142.2, 152.4, 162.0, 179.0,

(CO), 187 (CO), 191.8 (isoxazole C-5); MS: m/z = 510 ($M + 2$, 0.63%), 509 ($M + 1$, 2.63%), 508 (M^+ , 7.29%), 325 (10.94%), 172 (28.87%), 155 (100%), 128 (13.25%), 127 (95.07%), 115 (3.88%), 101 (7.19%), 89 (3.20%), 77 (15.19%), 65 (10.60%). Anal. calcd. for $C_{32}H_{20}N_4O_3$ (508.53): C, 75.58; H, 3.96; N, 11.02. Found: C, 75.77; H, 4.11; N, 11.15%.

5-[(3-{[4-Cyano-1-(4-methylphenyl)-5-phenylpyrazol-3-yl]carbonyl}isoxazol-4-yl)carbonyl]-2-(4-methylphenyl)-3-phenyl-5-hydropyrazole-4-carbonitrile (28e). Pale cream crystals from diluted AcOH, yield (88%), mp 174–176 °C; IR (KBr): 3053, 2921 (CH), 2235 (CN), 1385 (CH₃); ¹H NMR [(CD₃)₂SO]: δ = 2.34 (s, 3H, CH₃), 2.37 (s, 3H, CH₃), 7.14–7.95 (m, 14H, ArH's), 8.12 (d, 4H, J = 8 Hz), 8.45 (d, 4H, J = 8 Hz), 8.78 (s, 1H, isoxazole H-5); ¹³C NMR [(CD₃)₂SO]: (=20.1 (CH₃), 94.5, 109.8, 114.5, 117.2 (CN), 117.8 (CN), 125.5, 129.4, 129.7, 130.7, 132.2, 132.7, 136.8, 137.2, 138.2, 147.4, 151.4, 152.2, 159.8, 174.5 (CO), 179.7 (CO), 183.4 (isoxazole C-5); MS: m/z = 638 ($M - 1$, 1.25%), 601 (1.27%), 584 (1.1%), 286 (3.04%), 284 (5.2%), 243 (2.05%), 202 (3.55%), 167 (5.73%), 160 (5.05%), 149 (22.23%), 125 (19.45%), 103 (10.53%), 91 (39.33%), 81 (10.2%), 78 (17.00%), 77 (100%), 65 (52.98%). Anal. calcd. for $C_{39}H_{25}N_7O_3$ (639.66): C, 73.23; H, 3.94; N, 15.33. Found: C, 73.31; H, 4.12; N, 15.51%.

3-(2-P-Tolyl-2h-pyrazolo[3,4-d]pyridazin-4-yl)-1H-pyrazole-4-carbonitrile 24, 25 and 3-(7-Phenyl-isoxazolo[3,4-d]pyridazin-4-yl)-1-p-tolyl-1H-pyrazole-4-carbonitrile 29, 30

Equimolar amounts of each of the appropriate pyrazoles (**22a–e**, and **23a–e**), isoxazoles (**27a–e** and **28a–e**, 5 mmol), and hydrazine hydrate (1 ml, 99%) in ethanol (20 ml) were boiled under reflux for 2 h. The resulting solid was collected and crystallized to give pyrazolo[3,4-*d*]pyridazines (**24a–e** and **25a–e**) and isoxazolo[3,4-*d*]pyridazines (**29a–e** and **30a–e**), respectively.

3-(6,7-Dihydro-7-oxo-2-phenyl-2h-pyrazolo[3,4-d]pyridazin-4-yl)-1-phenyl-1H-pyrazole-4-carbonitrile (24a). Colorless crystals from AcOH, yield (84%), mp 322–324 °C; IR (KBr): 3381 (NH), 3059, (CH), 2230 (CN), 1684 (CO), 1591 (C=C); ¹H NMR [(CD₃)₂SO]: δ = 7.48–8.08 (m, 14H, ArH's), 9.21 (s, 1H, pyrazole H-5), 12.93 (s, br., 1H, NH); ¹³C NMR [(CD₃)₂SO]: (=104.5, 117.6 (CN), 120.5, 124.2 (pyrazole C-5), 125.6, 127.2, 128.4, 129.5, 129.9, 131.4, 131.6, 138.6, 139.6, 146.4, 148.2, 149.7, 154.2, 155.0 (CO); MS: m/z = 454 ($M - 1$, 4.3%), 453 (61.7%), 452 (95.7%), 425 (12.8%), 285 (10.8%), 227 (23.7%), 207 (12.8%), 138 (8.5%), 137 (12.8%), 136 (10.6%), 127 (12.8%), 104 (38.3%), 103 (17%), 102 (19.1%), 93 (10.6%), 92 (10.6%), 90 (8.5%), 89 (27.7%), 77 (100%), 65 (25.5%). Anal. calcd. for $C_{27}H_{17}N_7O$ (455.15): C, 71.20; H, 3.76; N, 21.53. Found: C, 71.35; H, 3.57; N, 21.72%.

3-(7-Methyl-2-phenyl-2h-pyrazolo[3,4-d]pyridazin-4-yl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (24b). Pale cream crystals from AcOH, yield (89%), mp 288–290 °C; IR (KBr): 3061, 2989 (CH), 2223 (CN), 1590 (C=C); ¹H NMR [(CD₃)₂SO]: δ = 2.93 (s, 3H, CH₃), 7.48–8.18 (m, 15H, ArH's), 9.41 (s, 1H, pyrazole H-5); ¹³C NMR [(CD₃)₂SO]: (=17.2 (CH₃), 104.5, 117.6 (CN), 122.5 (pyrazole C-5), 124.2, 126.6, 128.2, 129.7, 129.8, 131.2, 131.3, 139.3, 139.8, 143.2, 149.7, 151.6, 156.8,

168.1; MS: m/z = 455 ($M + 2$, 4.5%), 454 ($M + 2$, 15.9%), 453 (M^+ , 54.9%), 452 ($M - 1$, 87.3%), 321 (2.6%), 226 (4.9%), 190 (5.2%), 180 (6.4%), 115 (5.2%), 104 (7.9%), 77 (100%), 76 (20.6%), 64 (6.9%). Anal. calcd. for $C_{28}H_{19}N_7$ (453.5): C, 74.16; H, 4.22; N, 21.62. Found: C, 74.34; H, 4.40; N, 21.81%.

1,5-Diphenyl-3-(2,7-diphenyl-2H-pyrazolo[3,4-d]pyridazin-4-yl)-1H-pyrazole-4-carbonitrile (24c). Pale yellow crystals from AcOH, yield (90%), mp 300–302 °C; IR (KBr): 3057 (CH), 2225 (CN), 1635 (C=N), 1595 (C=C); 1H NMR [$(CD_3)_2SO$]: δ = 7.52–8.82 (m, 15H, ArH's), 9.53 (s, 1H, pyrazole H-5); ^{13}C NMR [$(CD_3)_2SO$]: (=104.5, 117.6 (CN), 120.5, 123.9, 124.0 (pyrazole C-5), 126.2, 127.2, 128.3, 129.1, 129.8, 131.0, 131.2, 131.4, 131.7, 136.2, 139.6, 139.7, 140.4, 149.8, 151.8, 156.0, 157.9; MS: m/z = 517 ($M + 2$, 3.12%), 516 ($M + 2$, 8.77%), 515 (M^+ , 22.02%), 300 (6.3%), 284 (30.87%), 257 (6.44%), 243 (10.82%), 184 (16.60%), 167 (7.67%), 140 (7.84%), 104 (38.53%), 77 (100%), 76 (20.6%), 65 (30.00%). Anal. calcd. for $C_{33}H_{21}N_7$ (515.57): C, 76.88; H, 4.11; N, 19.02. Found: C, 77.00; H, 4.25; N, 19.23%.

3-(4-(4-Cyano-1,5-diphenyl-1H-pyrazol-3-yl)-2-phenyl-2H-pyrazolo[3,4-d]pyridazin-7-yl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (24d). Yellow crystals from AcOH, yield (92%), mp >340 °C; IR (KBr): 3054 (CH), 2227 (CN), 1590 (C=C); 1H NMR [$(CD_3)_2SO$]: δ = 2.34 (s, 3H, CH_3), 7.26–8.15 (m, 24H, ArH's), 9.55 (s, 1H, pyrazole H-5); ^{13}C NMR [$(CD_3)_2SO$]: (=21 (CH_3), 96.5, 104.5, 117.6 (CN), 120.1, 122.2, 124.1, 127.2, 127.7 (CN), 128.3, 130.8, 131.2, 131.6, 133.2, 136.8, 139.4, 140.7, 141.6, 146.2, 147.1, 149.7, 151.7, 166.1, 166.6; MS: m/z = 696 (M^+ , 1.23%), 630 (1.53%), 572 (4.10%), 534 (3.19%), 439 (1.72%), 270 (7.62%), 167 (7.53%), 149 (21.87%), 135 (13.46%), 111 (7.06%), 97 (25.74%), 77 (100%), 69 (51.09%). Anal. calcd. for $C_{44}H_{28}N_{10}$ (696.76): C, 75.85; H, 4.05; N, 20.10. Found: C, 76.00; H, 3.85; N, 20.32%.

3-(6,7-Dihydro-7-oxo-2-p-tolyl-2H-pyrazolo[3,4-d]pyridazin-4-yl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (25a). Colorless crystals from dioxane, yield (85%), mp 272–274 °C; IR (KBr): 3425 (OH), 3062 (CH), 2233 (CN), 1728 (CO), 1658 (C=N), 1600 (C=C); 1H NMR [$(CD_3)_2SO$]: δ = 2.32 (s, 3H, CH_3), 7.26–8.09 (m, 14H, ArH's), 8.95 (s, 1H, pyrazole H-5), 12.21 (s, br., 1H, NH); ^{13}C NMR [$(CD_3)_2SO$]: δ = 20.2 (CH_3), 104.2, 117.6 (CN), 120.4, 124.1, 125.7 (pyrazole C-5), 127.2, 128.4, 129.1, 129.5, 129.8, 131.3, 131.6, 139.0, 139.8, 146.3, 148.1, 149.4, 145.2 (CO), 154.8; MS: m/z = 471 ($M + 2$, 2.04%), 470 ($M + 1$, 2.07%), 469 (M^+ , 16.58%), 380 (3.13%), 270 (3.25%), 243 (2.04%), 218 (2.17%), 165 (3.45%), 154 (2.49%), 127 (4.04%), 104 (14.86%), 92 (19.18%), 91 (19.79%), 78 (10.59%), 77 (100%), 65 (17.76%). Anal. calcd. for $C_{28}H_{19}N_7O$ (469.5): C, 71.63; H, 4.08; N, 20.88. Found: C, 71.75; H, 3.89; N, 21.00%.

3-(7-Methyl-2-p-tolyl-2H-pyrazolo[3,4-d]pyridazin-4-yl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (25b). Pale cream crystals from diluted AcOH, yield (89%), mp 218–220 °C; IR (KBr): 3043 (CH), 2235 (CN), 1643 (C=N), 1593 (C=C); 1H NMR [$(CD_3)_2SO$]: δ = 2.32 (s, 3H, CH_3), 2.61 (s, 3H, CH_3), 7.24–8.14 (m, 14H, ArH's), 8.92 (s, 1H, pyrazole H-5); ^{13}C NMR [$(CD_3)_2SO$]: δ = 17.1 (CH_3), 20.2 (CH_3), 104.2, 117.6 (CN), 121.1, 122.8 (pyrazole C-5), 123.7, 126.8, 128.4, 129.4, 129.8, 131.2, 131.4, 131.7, 139.4, 139.7, 143.2, 149.6, 151.7, 156.8, 168.1; MS: m/z = 467

(M^+ , 100%), 325 (13.14%), 333 (4.25%), 242 (8.46%), 230 (7.82%), 226 (5.74%), 219 (10.17%), 178 (10.09%), 151 (10.19%), 140 (11.75%), 127 (10.81%), 105 (9.97%), 90 (41.27%), 91 (19.79%), 78 (10.59%), 77 (49.45%), 65 (25.39%). Anal. calcd. for $C_{29}H_{21}N_7$ (467.52): C, 74.50; H, 4.53; N, 20.97. Found: C, 74.34; H, 4.35; N, 21.15%.

1,5-Diphenyl-3-(7-phenyl-2-p-tolyl-2H-pyrazolo[3,4-d]pyridazin-4-yl)-1H-pyrazole-4-carbonitrile (25c). Yellow crystals from diluted AcOH, yield (90%), mp 252–254 °C; IR (KBr): 3058 (CH), 2229 (CN), 1593 (C=C); 1H NMR $[(CD_3)_2SO]$: δ = 2.32 (s, 3H, CH_3), 7.24–8.24 (m, 20H, ArH's), 8.95 (s, 1H, pyrazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: δ = 20.1 (CH_3), 104.2, 117.6 (CN), 123.8, 123.9 (pyrazole C-5), 127.6, 128.2, 128.8, 129.3, 129.9, 131.0, 131.2, 131.3, 131.6, 136.2, 139.5, 139.8, 140.5, 149.8, 151.5, 156.7, 157.8; MS: m/z = 529 (M^+ , 0.34%), 310 (65.23%), 296 (84.69%), 284 (9.82%), 269 (45.46%), 254 (32.53%), 241 (17.80%), 231 (11.79%), 228 (18.44%), 221 (17.75%), 196 (7.12%), 177 (32.30%), 165 (14.05%), 162 (52.45%), 155 (58.13%), 148 (28.88%), 90 (100%), 76 (39.48%), 65 (51.97%). Anal. calcd. for $C_{34}H_{23}N_7$ (529.59): C, 77.11; H, 4.38; N, 18.51. Found: C, 77.25; H, 4.42; N, 18.35%.

3-(4-(4-Cyano-5-phenyl-1-p-tolyl-1H-pyrazol-3-yl)-2-p-tolyl-2H-pyrazolo[3,4-d]pyridazin-7-yl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (25d). Yellow crystals from diluted AcOH, yield (92%), mp >330 °C; IR (KBr): 3033 (CH), 2229 (CN), 1598 (C=C); 1H NMR $[(CD_3)_2SO]$: δ = 2.32 (s, 6H, $2CH_3$), 7.24–8.31 (m, 23H, ArH's), 8.85 (s, 1H, pyrazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: δ = 20.1 (CH_3), 95.3, 104.2, 117.6 (CN), 119.1 (pyrazole), 122.2, 124.8, 126.1, 126.7, 127.1, 127.7 (CN), 128.3, 129.4, 130.9, 131.4, 131.6, 133.2, 136.7, 139.9, 140.7, 141.4, 146.2, 147.1, 149.6, 151.7, 166.2, 166.8; MS: m/z = 711 (M^+ , 2.37%), 570 (6.14%), 300 (5.81%), 285 (4.25%), 259 (13.68%), 241 (5.54%), 219 (4.88%), 194 (4.22%), 180 (10.05%), 191 (4.39%), 177 (3.58%), 166 (6.30%), 154 (3.01%), 150 (4.10%), 147 (10.21%), 127 (8.46%), 114 (9.46%), 104 (25.98%), 91 (43.81%), 77 (100%), 65 (43.62%). Anal. calcd. for $C_{45}H_{30}N_{10}$ (710.79): C, 76.04; H, 4.25; N, 19.71. Found: C, 75.85; H, 4.12; N, 19.94%.

1,5-Diphenyl-3-(7-phenylisoxazolo[4,3-d]pyridazin-4-yl)-1H-pyrazole-4-carbonitrile (29a). Colorless crystals from EtOH, yield (89%), mp 248–250 °C; IR (KBr): 3058 (CH), 2233 (CN), 1596 (C=C); 1H NMR $[(CD_3)_2SO]$: δ = 7.24–8.31 (m, 15H, ArH's), 8.65 (s, 1H, oxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: δ = 104.2, 113.6, 119.0 (CN), 123.8, 128.2, 128.7, 129.3, 129.8, 131.2, 131.3, 131.5, 131.7, 136.3, 141.7, 148.2, 149.6, 150.4 (oxazole C-5), 153.2, 156.2, 158.6; MS: m/z = 442 ($M+1$, 11.36%), 441 (M^+ , 32.29%), 338 (10.01%), 310 (5.99%), 272 (11.69%), 180 (19.40%), 172 (30.21%), 155 (22.20%), 141 (13.80%), 127 (37.98%), 115 (22.05%), 105 (18.37%), 77 (100%), 65 (11.24%). Anal. calcd. for $C_{27}H_{16}N_6O$ (440.46): C, 73.63; H, 3.66; N, 19.08. Found: C, 73.82; H, 3.45; N, 19.12%.

3-(7-(Furan-2-yl)isoxazolo[4,3-d]pyridazin-4-yl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (29b). Brown crystals from diluted AcOH yield (89%), mp 280–282 °C; IR (KBr): 3028 (CH), 2229 (CN), 1593 (C=C); 1H NMR $[(CD_3)_2SO]$: δ = 6.68 (d, 1H, J = 8 Hz, furan H-3), 7.24–8.31 (m, 12H, ArH's), 8.65 (s, 1H, oxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: δ = 104.2, 112.2, 113.4, 116.5, 118.6 (CN), 123.9, 128.6, 129.6, 129.9, 131.2, 131.6, 131.8, 141.3, 148.4, 149.2 (oxazole C-5),

149.7, 150.6, 153.4, 153.8, 157.6, 158.5; MS: $m/z = 432$ ($M + 2$, 1.66%), 431 ($M + 1$, 6.01%), 430 (M^+ , 30.93%), 338 (3.74%), 310 (3.01%), 272 (7.53%), 244 (3.73%), 180 (25.30%), 141 (9.46%), 123 (4.12%), 104 (14.03%), 77 (100%), 65 (4.54%). Anal. calcd. for $C_{25}H_{14}N_6O_2$ (430.42): C, 69.76; H, 3.28; N, 19.53. Found: C, 69.65; H, 3.18; N, 19.75%.

1,5-Diphenyl-3-(7-(thien-2-yl)isoxazolo[4,3-d]pyridazin-4-yl)-1H-pyrazole-4-carbonitrile (29c). Yellow crystals from diluted AcOH yield (89%), mp 284–286 °C; IR (KBr): 3066 (CH), 2233 (CN), 1600 (C=C); 1H NMR $[(CD_3)_2SO]$: $\delta = 7.24$ – 8.41 (m, 13H, ArH's), 8.85 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: $\delta = 104.2$, 111.6, 116.1, 118.7 (CN), 125.8, 129.7, 129.9, 131.2, 131.4, 131.7, 140.4, 141.6, 147.7 (oxazole C-5), 149.7, 149.9, 150.8, 154.5, 154.7, 156.5, 167.2; MS: $m/z = 448$ ($M + 1$, 4.10%), 446 (M^+ , 38.72%), 338 (3.74%), 391 (5.84%), 310 (5.84%), 272 (8.75%), 180 (27.59%), 141 (13.43%), 123 (15.19%), 110 (10.19%), 104 (9.89%), 77 (100%), 65 (5.99%). Anal. calcd. for $C_{25}H_{14}N_6OS$ (446.48): C, 67.25; H, 3.16; N, 18.82; S, 7.18. Found: C, 67.37; H, 3.04; N, 18.98; S, 7.33%.

3-(7-(Naphthalen-2-yl)isoxazolo[4,3-d]pyridazin-4-yl)-1,5-diphenyl-1H-pyrazole-4-carbonitrile (29d). Pale yellow crystals from diluted AcOH yield (90%), mp 258–260 °C; IR (KBr): 3058 (CH), 2225 (CN), 1593 (C=C); 1H NMR $[(CD_3)_2SO]$: $\delta = 7.28$ – 8.33 (m, 16H, ArH's), 8.83 (s, 1H, ArH), 8.85 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: $\delta = 104.2$, 118.6 (CN), 123.1, 125.4, 125.7, 126.4, 126.6, 127.4, 128.7, 129.7, 129.9, 131.1, 131.2, 131.3, 131.4, 131.45, 140.0, 141.4, 149.2, 149.7, 153.1, 154.5, 157.8, 163.0; MS: $m/z = 490$ (M^+ , 1.10%), 489 ($M - 1$, 1.0%), 311 (3.74%), 255 (5.84%), 77 (45.36%). Anal. calcd. for $C_{31}H_{18}N_6O$ (490.51): C, 75.91; H, 3.70; N, 17.13. Found: C, 76.11; H, 3.85; N, 17.26%.

3-(4-(4-Cyano-1,5-diphenyl-1H-pyrazol-3-yl)isoxazolo[4,3-d]pyridazin-7-yl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (29e). Pale cream crystals from diluted AcOH yield (92%), mp 242–244 °C; IR (KBr): 3060 (CH), 2235 (CN), 1597 (C=C); 1H NMR $[(CD_3)_2SO]$: $\delta = 2.32$ (s, 3H, CH_3), 7.24–8.33 (m, 19H, ArH's), 8.85 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: $\delta = 20.1$ (CH_3), 95.4, 104.2, 110.7, 118.6 (CN), 123.7, 127.8, 128.3, 129.8, 130.8, 131.4, 131.8, 133.2, 136.8, 141.4, 142.8, 146.3 (isoxazole C-5), 147.5, 149.3, 154.6, 165.7, 167.8. Anal. calcd. for $C_{38}H_{23}N_9O$ (621.65): C, 73.42; H, 3.73; N, 20.28. Found: C, 73.24; H, 3.85; N, 20.42%.

5-Phenyl-3-(7-phenylisoxazolo[4,3-d]pyridazin-4-yl)-1-p-tolyl-1H-pyrazole-4-carbonitrile (30a). Colorless crystals from diluted AcOH yield (89%), mp 270–272 °C; IR (KBr): 3044 (CH), 2225 (CN), 1617 (C=N), 1576 (C=C); 1H NMR $[(CD_3)_2SO]$: $\delta = 2.34$ (s, 3H, CH_3), 7.19–8.14 (m, 14H, ArH's), 8.84 (s, 1H, isoxazole H-5); ^{13}C NMR $[(CD_3)_2SO]$: $\delta = 20.1$ (CH_3), 104.2, 113.4, 118.6 (CN), 124.5, 128.3, 128.4, 129.9, 131.1, 131.6, 133.6, 136.2, 136.4, 142.5, 148.4, 149.3, 150.5 (isoxazole C-5), 152.9, 156.8, 158.5. Anal. calcd. for $C_{28}H_{18}N_6O$ (454.48): C, 74.00; H, 3.99; N, 18.49. Found: C, 74.15; H, 4.18; N, 18.67%.

3-[7-(2-Furyl)isoxazolo[3,4-d]pyridazin-4-yl]-1-(4-methylphenyl)-5-phenyl-1H-pyrazole-4-carbonitrile (30b). Deep brown from diluted AcOH yield (89%), mp 242–244 °C; IR (KBr): 3066 (CH), 2233 (CN), 1600 (C=C); 1H NMR

$[(\text{CD}_3)_2\text{SO}]$: $\delta = 2.34$ (s, 3H, $\text{CH}_3\text{C}_6\text{H}_4$), 6.92–8.23 (m, 12H, ArH's), 8.93 (s, 1H, isoxazole H-5); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta = 20.1$ (CH_3), 104.2, 112.1, 113.4, 116.8, 117.8 (CN), 124.2, 128.6, 129.8, 131.4, 131.5, 133.0, 136.7, 142.1, 148.2, 149.8 (isoxazole C-5), 150.4, 153.5, 153.8, 156.8, 158.2; MS: $m/z = 446$ (0.44%), 310 (79.38%), 296 (100%), 284 (11.96%), 291 (53.33%), 268 (52.26%), 255 (34.69%), 228 (20.76%), 215 (18.35%), 203 (25.10%), 193 (31.06%), 189 (16.10%), 194 (11.84%), 177 (35.26%), 167 (18.29%), 165 (14.52%), 151 (25.14%), 140 (44.05%), 134 (19.04%), 114 (33.09%), 131 (15.78%), 100 (30.71%), 91 (72.61%), 88 (31.98%), 76 (48.90%), 65 (59.48%). Anal. calcd. for $\text{C}_{26}\text{H}_{16}\text{N}_6\text{O}_2$ (444.44): C, 70.26; H, 3.63; N, 18.91. Found: C, 70.45; H, 3.72; N, 19.07%.

5-Phenyl-3-(7-(thien-2-yl)isoxazolo[4,3-d]pyridazin-4-yl)-1-p-tolyl-1H-pyrazole-4-carbonitrile (30c). Brown crystals from EtOH yield (89%), mp 238–240 °C; IR (KBr): 3066 (CH), 2233 (CN), 1600 (C=C); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta = 2.34$ (s, 3H, CH_3), 7.24–8.41 (m, 12H, ArH's), 8.85 (s, 1H, isoxazole H-5); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta = 20.1$ (CH_3), 113.4, 118.8 (CN), 124.2, 127.4, 128.3, 129.8, 131.6, 131.7, 132.5, 123.7, 133.2, 136.1, 139.4, 142.2, 148.3, 149.2 (isoxazole C-5), 149.9, 158.5, 160.4, 162.8; MS: $m/z = 462$ ($\text{M} + 2$, 16.39%), 461 ($\text{M} + 1$, 8.88%), 460 (M^+ , 16.39%), 448 (20.45%), 477 (5.63%), 405 (7.25%), 390 (5.09%), 352 (12.13%), 315 (17.84%), 286 (15.91%), 231 (11.31%), 194 (37.18%), 155 (10.95%), 128 (15.81%), 123 (26.57%), 121 (30.89%), 111 (23.92%), 110 (17.92%), 104 (22.91%), 96 (23.00%), 91 (100%), 77 (56.98%), 65 (77.35%). Anal. calcd. for $\text{C}_{26}\text{H}_{16}\text{N}_6\text{OS}$ (460.11): C, 67.81; H, 3.50; N, 18.25; S, 6.96. Found: C, 67.71; H, 3.68; N, 18.12; S, 7.15%.

3-(7-(Naphthalen-2-yl)isoxazolo[4,3-d]pyridazin-4-yl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (30d). Colorless crystals from diluted AcOH yield (87%), mp: 278–280 °C; IR (KBr): 3047 (CH), 2225 (CN), 1577 (C=C); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta = 2.34$ (s, 3H, CH_3), 7.24–8.41 (m, 16H, ArH's), 8.85 (s, 1H, isoxazole H-5); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta = 20.1$ (CH_3), 113.4, 118.8 (CN), 123.2, 124.4, 125.3, 127.2, 127.4, 128.2, 129.8, 130.5, 131.4, 131.6, 131.7, 133.4, 136.6, 142.4, 148.0, 149.5, 150.6 (isoxazole C-5), 152.9, 156.6, 158.4. Anal. calcd. for $\text{C}_{32}\text{H}_{20}\text{N}_6\text{O}$ (504.54): C, 76.18; H, 4.00; N, 16.66. Found: C, 76.24; H, 4.11; N, 16.82%.

3-(4-(4-Cyano-5-phenyl-1-p-tolyl-1H-pyrazol-3-yl)isoxazolo[4,3-d]pyridazin-7-yl)-5-phenyl-1-p-tolyl-1H-pyrazole-4-carbonitrile (30e). Pale cream crystals from diluted AcOH yield (92%), mp 258–260 °C; IR (KBr): 3047 (CH), 2226 (CN), 1625 (1577 (C=C)); ^1H NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta = 2.34$ (s, 3H, CH_3), 7.24–8.41 (m, 16H, ArH's), 8.85 (s, 1H, oxazole H-5); ^{13}C NMR $[(\text{CD}_3)_2\text{SO}]$: $\delta = 20.1$ (2 CH_3), 95.6, 104.3, 110.6, 113.4, 118.8 (CN), 124.2, 127.4, 128.3, 129.6, 130.8, 131.6, 133.2, 136.4, 141.2, 142.4, 142.8, 146.6 (isoxazole C-5), 147.2, 148.7, 149.7, 154.3, 165.2, 167.5. Anal. calcd. for $\text{C}_{39}\text{H}_{25}\text{N}_9\text{O}$ (635.68): C, 73.69; H, 3.96; N, 19.83. Found: C, 73.69; H, 3.96; N, 19.83%.

REFERENCES

1. Taylor, E. C.; Hartke, K. S. The reaction of malononitrile with substituted hydrazines: New routes to 4-aminopyrazolo[3,4-d]pyridazines. *J. Am. Chem. Soc.* **1959**, *81*, 2456–2464.

2. Ho, Y. W. Synthesis of some new azopyrazolo[1,5-a]pyrimidine-thieno[2,3-b]pyridine derivatives and their application as disperse dyes. *Dyes Pigm.* **2005**, *64*, 223–230.
3. Singh, S. P.; Kumer, D. Reinvestigation of the reported synthesis of naphtho[2',1'-4,5]thiazolo[2,3-c][1,2,4]triazepins. *Heterocycles* **1990**, *31*, 855–860.
4. Langenscheid, K.; Luduing, G. Substituted 5-amino-4-formylcarbamoylpyrazoles. German Patent 2508, 1975; *Chem Abstr.* **1976**, *85*, 78124, *Chem. Abstr.* **1976**, *84*, 44041e.
5. Anderson, E. L.; Lasey, J. F.; Greene, L. C.; Lafferty, J. L.; Reift, H. E. Synthesis and muscle relaxant properties of 3-amino-4-arylazopyrazoles. *J. Med. Chem.* **1964**, *7*, 259–268.
6. Elkhawaga, A. M.; Kama-El-Dean, A. M.; Radwan, S. M.; Ahmed, M. M. Synthesis of some imidazopyrazolopyrimidines, pyrazolopyrimidopyrimidines, and pyrazolpyrimidinothiazines. *Bull. Korean. Chem. Soc.* **2009**, *30*, 561–566.
7. Mohanty, S. K.; Sridhar, P.; Sundar, R.; Mittra, A. S. Fungicidal activity & synthesis of 5-thiopyrazolones and compounds having α -pyrone attached to pyrazolin nucleus. *Indian J. Chem.* **1977**, *15B*, 1146–1148.
8. Sternbach, L. M. The benzodiazepine story. *Prog. Drug. Res.* **1978**, *22*, 229.
9. Jaiswal, N.; Jaiswal, R.; Barhwal, J.; Kishor, K. Synthesis & biological activity of some new 10-[(3,5-diaryl-2-pyrazolin-1-yl)acetyl]-phenothiazines. *Indian J. Chem.* **1981**, *20B*, 252 (2456).
10. Henning, G. Pyrazoline azo dyes. *Germain Patent* 261698, **1977**; *Chem. Abstr.* **1978**, *88*, 38948v.
11. Jain, R.; Shukla, A. *J. Indian Chem. Soc.* **1990**, *67*, 575.
12. Skippe, H. E.; Robins, R. K.; Thomson, J. R.; Ching, C. C.; Brockman, R. W.; Schable, F. M. Structure–activity relationships observed on screening a neoplasms series of pyrazolopyrimidines against experimental. *Cancer Res.* **1957**, *17*, 579–596.
13. Skippe, H. E.; Robins, R. K.; Thomson, J. R. Inhibition of experimental neoplasms by 4-aminopyrazolo[3,4-d]pyrimidine. *Proc. Soc. Exptl. Biol. Med.* **1955**, *89*, 594–596.
14. Tominaga, Y.; Honkawa, Y.; Hara, M.; Hosomi, A. Synthesis of pyrazolo[3,4-d]pyrimidine derivatives using ketene dithioacetals. *J. Heterocycl. Chem.* **1990**, *27*, 775–783.
15. Moukha-chafiq, O.; Taha, M. L.; Lazrek, H. B.; Vasseur, J.-J.; Pannecouque, C.; Witvrouw, M.; De Clercq, E. Synthesis and biological activity of some 4-substituted 1-[1-(2,3-dihydroxy-1-propoxy)methyl-1,2,3-triazol-(4 and 5)-ylmethyl]-1H-pyrazolo[3,4-d]pyrimidines. *Farmaco*, **2002**, *57*, 27–32; *Chem. Abstr.* **2002**, *137*, 93724z.
16. Lowe, P. A. Aromatic and heteroaromatic chemistry. In *Heterocyclic Chemistry*; H. Suschitzky and O. Meth-Cohn (Eds.); Chemical Society: London, 1980; vol. 1, pp. 119–139.
17. Metzger, J. V. Thiazols and their benzo derivatives. In *Comprehensive Heterocyclic Chemistry*; A. R. Katritzky and C. W. Rees (Eds.); Pergamon Press: Oxford, UK, 1984; vol. 6, p. 328.
18. Brown, H. D. 2-Pyrynyl and 2-thiopyrynyl benzazoles. U.S. Patent, 3,278,547, 1966, *Chem. Abstr.* **1966**, *65*, 18593.
19. Singh, S. P.; Segal, S. Synthesis and phototoxicity of some 2-(phenyl or 2- or 3-thienyl)-4-substituted thiazoles. *Indian J. Chem. B* **1988**, *27*, 941.
20. Usui, Y.; Yamano, T.; Fungicides, X. Antifungal activity of 3-aminothiazoline-2-thione and 4H-1,3,4-thiadiazine derivatives. *Yakugaku Zasshi* **1969**, *89*, 099; *Chem. Abstr.* **1969**, *71*, 69601.
21. Goursot, P.; Westrum Jr., E. F. Heat capacity and thermodynamic properties of benzothiazol from 5 to 320 K. *J. Chem. Eng. Data* **1969**, *14*, 1.
22. Abdelhamid, A. O.; Ismail, Z. H.; Abdel-Gawad, S. M.; Ghorab, M. M.; Abdel-Aziem, A. Synthesis of some new thieno[2,3-b]pyridine, pyrimidino[4',5:4,5]thieno[2,3-b]-pyridine, and 2,3-dihydro-1,3,4-thiadiazole. *Phosphorus, Sulfur Silicon Relat. Elem.* **2009**, *184*, 58–75.
23. Abdelhamid, A. O.; Afifi, M. A. Synthesis Of some new thiazoles and pyrazolo[1,5-a]pyrimidines containing antipyrine moiety. *Synth. Commun.* **2010**, *40*, 1539–1550.

24. Abdelhamid, A. O.; Abdelall, E. K. A.; Zaki, Y. H. Reactions with hydrazonoyl halides 62: Synthesis of some new imidazo[1,2-*a*]pyrimidine, imidazo[1,2-*a*]pyridine, imidazo[1,2-*b*]pyrazole, and quanazoline derivatives. *J. Heterocycl. Chem.* **2010**, *47*, 477–482.
25. Abdelhamid, A. O. Convenient synthesis of some new pyrazolo[1,5-*a*]pyrimidine, pyridine, thieno[2,3-*b*]pyridine, and isoxazolo[3,4-*d*]pyridazine derivatives containing benzofuran moiety. *J. Heterocycl. Chem.* **2009**, *46*, 680–686 (2009).
26. Abdelhamid, A. O.; Abdelall, E. K. A.; Abdel-Riheem, N. A.; Ahmed, S. A. Synthesis and antimicrobial activity of some new 5-arylazothiazole, pyrazolo[1,5-*a*]pyrimidine, [1,2,4]triazolo[4,3-*a*]pyrimidine, and pyrimido[1,2-*a*]benzimidazole derivatives containing the thiazole moiety. *Phosphorus, Sulfur Silicon Relat. Elem.* **2010**, *185*, 709–718.
27. Abdelall, E. K. A.; Mohamed, M. A.; Abdelhamid, A. O. Reactions with hydrazonoyl halides 63: synthesis and anticancer activity of some new 1,3,4-thiadiazoles, 1,3,4-selenadiazoles, and 1,2,4-triazolo[4,3-*a*]pyrimidines. *Phosphorus, Sulfur, Silicon Relat. Elem.* **2010**, *185*, 1862–1874.
28. Abdelhamid, A. O.; Afifi, M. A. Utility of 4-formylantipyrine in heterocyclic synthesis. *J. Adv. Chem.* **2010**, *1*, 137.
29. Abdelhamid, A. O.; Shokry, A. S.; Tawfik, S. M. A new approach for the synthesis of some pyrazolo[5,1-*c*]triazines and pyrazolo[1,5-*a*]pyrimidines containing naphthofuran moiety. *J. Heterocycl. Chem.* **2012**, *49*, 116.